Life Science Informatics Publications
Research Journal of Life Sciences, Bioinformatics, Pharmaceutical and Chemical Sciences

Original Research Article
DOI: 10.26479/2019.0506.03
MATLAB MACHINE LEARNING \& CURVE-FITTING TOOLBOX: PREDICTION OF DRUG AQUEOUS SOLUBILITY

Kamal I.M. AI-Malah*<br>Chemical Engineering, Higher Colleges of Technology, Ruwais, Abu-Dhabi, UAE.


#### Abstract

The prediction of aqueous solubility of a set of 246 drug molecules with a broad range, varying from 120 up to $8,330 \mathrm{mg} / \mathrm{L}$, as a function of pertinent molecular properties was examined. MATLAB® Machine Learning (ML) and Optimization Toolbox were used in the data analysis. Both the supervised and supervised learning techniques were used to analyze such highly scattered date, like aqueous solubility of organic drug molecules. The exotic features of machine learning algorithms were shown in the form of figures, pertinent to the selection process of predictor variables. It was found that the drug aqueous solubility data could be best described by the first three important molecular properties: the non-polar molecular mass, $M W N P O L$, the non-polar molar volume, NPolVol, and the polar fraction of a molecule, PolFrac, as the third refining or tuning-up factor (weight parameter in curve fitting). The polarity index was evaluated based on the atomic molefraction of polar atoms, namely, $\mathrm{F}, \mathrm{O}, \mathrm{N}, \mathrm{Cl}$, and Br because such atoms have relatively higher electronegativity values than those of C, H, I, P, and S atoms. The percent relative error (PRE) was also calculated for each individual drug molecule using models based on MWNPOl, NPolVol, and PolFrac, while assuming that the true value of solubility is the experimentally measured and reported value. It was found that the three models overestimated the aqueous solubility of less soluble materials; specifically, below $200 \mathrm{mg} / \mathrm{L}$. Finally, the entropically driven hydrophobic interactions, manifested via $M W N P O L$, were found to act as anti-solvation factor.


Keywords: MATLAB; Machine Learning; Optimization; Drug Aqueous Solubility.

Article History: Received: September 03, 2019; Revised: October 20, 2019; Accepted: November 11, 2019.

# Corresponding Author: Dr. Kamal I. Al-Malah* Ph.D. <br> Chemical Engineering, Higher Colleges of Technology, Ruwais, Abu-Dhabi, UAE. <br> E-mail Address: kalmalah@hct.ac.ae, almalak61@hotmail.com. 

## 1. INTRODUCTION

As pointed out earlier [1], "Organic solvents play a critical role in many industrial applications, while they pose a direct impact on health, safety, environmental, feasibility, and economic aspects of a chemical, biochemical, food, and pharmaceutical industries. Of an immense concern, the solubilization of pharmaceutical active ingredients ranks a top priority for injected and oral drug administration. With an increasing pressure to identify high-quality drug candidates, it is critical to assess the Absorption, Distribution, Metabolism, Excretion (ADME) attributes of compounds early during drug discovery stage. This may include properties such as aqueous and non-aqueous solubility, permeability, metabolic stability, and in vivo pharmacokinetics". Eric et al. [2] worked on an approach for the development of a model for prediction of aqueous solubility, based on the implementation of an algorithm for the automatic adjustment of descriptor's relative importance (AARI) in counter-propagation artificial neural networks (CPANN). Using their approach, the interpretability of the model based on artificial neural networks, traditionally considered as "black box" models, was significantly improved. For the development of the model, a data set consisting of 374 diverse drug-like molecules, divided into training ( $\mathrm{n}=280$ ) and test ( $\mathrm{n}=94$ ) sets using self-organizing maps, was used. Heuristic method was applied in preselecting a small number of the most significant descriptors to serve as inputs for CPANN training. The performances of the final model based on 7 descriptors for prediction of solubility were satisfactory for both training and test set. The model was found to be a highly interpretable in terms of solubility, as well as rationalizing structural features that could have an impact on the solubility of the compounds investigated. Their proposed approach can significantly enhance model usability by giving guidance for structural modifications of compounds with the aim of improving solubility in the early phase of drug discovery. Sun et al. [3] emphasized the aqueous solubility as one of the most important properties in drug discovery, as it has profound impact on various drug properties, including biological activity, pharmacokinetics (PK), toxicity, and in vivo efficacy. They developed predictive models for kinetic solubility with in-house data generated from 11,780 compounds collected from over 200 NCATS intramural research projects. Based on the customized atom type descriptors, the support vector classification (SVC) models were trained on $80 \%$ of the whole dataset, and exhibited high predictive performance for estimating the solubility of the remaining $20 \%$ compounds within the test set. Their predictive models of aqueous solubility could be even used to identify insoluble compounds in drug discovery pipeline; to provide design ideas for improving solubility by analyzing the atom types associated with poor solubility; and to prioritize compound libraries to be purchased or synthesized. In previous works, the aqueous solubility of simple inorganic [4]
© 2019 Life Science Informatics Publication All rights reserved Peer review under responsibility of Life Science Informatics Publications

Al-Malah RJLBPCS 2019 and that of simple (single-carbon) organic [5] molecules were examined and expressed in terms of important molecular properties. Moreover, the aqueous solubility of some organic solvents was examined as a function of some selected molecular descriptors which are thought to affect the solvation process. It was found that to have an organic solvent with a high aqueous solubility, it has to have a low value of both the log partition coefficient between octanol and water, LogKow, and the molecular rugosity, $\mathrm{R}=\mathrm{V} / \mathrm{S}$, accompanied by a high value of polar to hydrophobic surface area ratio, PHSAR [6]. In addition, paracetamol, also known as acetaminophen, N-(4hydroxyphenyl)ethanamide, N -(4-hydroxyphenyl)acetamide, or N -acetyl-p-aminophenol, APAP, a medicine used to treat pain and fever, was used as a solid solute to demonstrate how the Aspen Plus simulator could be used as a powerful tool to optimize its solubility, using different organic solvents and water, as well. The minimization of molar Gibbs free energy of a mixture and the maximization of paracetamol solubility were both used as objective functions, from an optimization standpoint [1]. In this work, a set of 246 selected drug molecules were analyzed in light of deciphering the relationship between their aqueous solubilities on the one hand and some of their molecular and physical properties on the other hand. MATLAB Machine Learning (ML) and Optimization Toolbox were both used to analyze the degree of relationship for each player and later quantify such relationships, by expressing the aqueous solubility as a function of the most pertinent and important variables.

## 2. MATERIALS AND METHODS

MATLAB® has versatile built-in powerful functions which are meant to analyze data, characterized by a significant degree of scatter or bias, and later to decipher the unknown relationship between the dependent variable (or, response variable) and the list of independent variables (or, predictor variables). Each function will be explained on the spot once it is introduced to the reader. Let us briefly introduce what machine learning is all about.

### 2.1 What is Machine Learning?

As quoted by MATLAB R2019a built-in help, machine learning teaches computers to do what comes naturally to humans: Learn from experience. Machine learning algorithms utilize computational methods to directly learn (or extract) information from data without relying on a deterministic model. The set of algorithms adaptively improve their performance as the number of samples available for learning increases. Machine learning uses two types of techniques: Supervised learning, which trains a model on known input (predictor) and output (response) data so that it can predict future outputs, and unsupervised learning, which finds hidden patterns or intrinsic structures in input data. The aim of supervised machine learning is to build a model that makes predictions based on evidence in the presence of uncertainty. A supervised learning
(C) 2019 Life Science Informatics Publication All rights reserved algorithm takes a known set of input data and known responses to the data (output) and trains a model to generate reasonable predictions for the response to new data. Supervised learning uses classification and regression techniques to develop predictive models. On the one hand, classification techniques predict categorical responses; for example, whether an email is genuine or spam, or whether a tumor is cancerous or benign. Classification models classify input data into categories. Typical applications include medical imaging, image and speech recognition, and credit scoring. On the other hand, regression techniques predict continuous responses, for example, changes in temperature or fluctuations in power demand. Typical applications include electricity load forecasting and algorithmic trading. Machine learning algorithms enable the data analyst to prioritize the input variables based on their impact on or contribution to the response (output) variable. In other words, the investigator can prioritize the list of variables as far as their importance or contribution to the overall portray of the aqueous solubility is concerned. Optimization techniques can then be implemented on the mini set of input variables. In brief, machine learning will facilitate the process of ending up with a deterministic model, in the form of $y=f(X)=f\left(x_{1}, x_{2}\right)$ only rather than having $y=f(X)=f\left(x_{1}, x_{2}, x_{3}, \ldots, x_{n}\right)$, at large.

### 2.2 Molecular Properties

Table 1 shows 246 drug components and their physical properties. From left, we have the name of the component, its molecular formula, its molecular mass ( $\mathrm{g} / \mathrm{mol}$ ), its aqueous solubility, expressed in $\mathrm{mg} / \mathrm{L}$, its solid density $\left(\mathrm{g} / \mathrm{cm}^{3}\right)$, its boiling point, expressed in ${ }^{\circ} \mathrm{C}$, and finally its melting point, expressed in ${ }^{\circ} \mathrm{C}$. Molecular data were substantially borrowed from Cao et al. [7] and Yalksowsky [8]. If any molecular data were missing, then, web databanks would be sought, like: www.chemicalbook.com, www.ncbi.nlm.nih.gov, www.chemspider.com, and www.epa.gov.

It is worth mentioning here that there is a pronounced discrepancy in terms of reporting the aqueous solubility value between one source and another. Moreover, even quoting from one source, there is still more than one reported value, depending on the original source of the data. For instance, the handbook [8] itself is a compilation of data, quoted from different sources. In addition, physical and toxicological properties of a drug-like compound may be affected by carrier solvents in commercial formulations. In addition, the boiling point for more than one case is quoted as predicted, but not experimentally measured. An average value was taken should there be more than a value of aqueous solubility. The advantage of having highly biased/scattered data will make ML algorithms more demanding and challenging in terms of deciphering the sacred relationship between the response on one side and predators (predictors) on another side.

Table 1: Drug compounds and their molecular properties.

| NAME | Molecular Formula | MW (g/mol) | Aq. Sol (mg/L) | Density $\left(\mathrm{g} / \mathrm{cm}^{3}\right)$ | $\begin{aligned} & \hline \mathbf{B P} \\ & \left({ }^{\circ} \mathbf{C}\right) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline \text { MP } \\ & \left({ }^{\circ} \mathbf{C}\right) \\ & \hline \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1,6-Cleve's acid | $\mathrm{C}_{10} \mathrm{H}_{9} \mathrm{NO}_{3} \mathrm{~S}$ | 223.2 | 3000 | 1.502 | 434.2 | 173 |
| 1_naphthol | $\mathrm{C}_{10} \mathrm{H}_{8} \mathrm{O}$ | 144.2 | 3176 | 1.100 | 279 | 95 |
| 2,4,5-trichlorophenol | $\mathrm{C}_{6} \mathrm{H}_{3} \mathrm{Cl}_{3} \mathrm{O}$ | 197.4 | 3079 | 1.600 | 248 | 68 |
| 2,4-DB | $\mathrm{C}_{10} \mathrm{H}_{10} \mathrm{Cl}_{2} \mathrm{O}_{3}$ | 249.1 | 1663 | 1.400 | 410 | 119 |
| 2,6- <br> Dibromoquinone-4chlorimide | $\mathrm{C}_{6} \mathrm{H}_{2} \mathrm{Br}_{2} \mathrm{ClNO}$ | 299.3 | 1770 | 2.200 | 296 | 80 |
| 2-Amino-5bromobenzoic acid | $\mathrm{C}_{7} \mathrm{H}_{6} \mathrm{BrNO}_{2}$ | 216.0 | 2260 | 1.800 | 342 | 213 |
| 2-Cyclohexyl-4,6dinitrophenol | $\mathrm{C}_{12} \mathrm{H}_{14} \mathrm{~N}_{2} \mathrm{O}_{5}$ | 266.2 | 1168 | 1.400 | 321 | 107 |
| 2-Ethyl-1-hexanol | $\mathrm{C}_{8} \mathrm{H}_{18} \mathrm{O}$ | 130.2 | 2944 | 0.830 | 185 | -76 |
| 2-Naphthol | $\mathrm{C}_{10} \mathrm{H}_{8} \mathrm{O}$ | 144.2 | 740 | 1.280 | 285 | 122 |
| 3,4-Dinitrobenzoic acid | $\mathrm{C}_{7} \mathrm{H}_{4} \mathrm{~N}_{2} \mathrm{O}_{6}$ | 212.1 | 3826 | 1.674 | 459 | 165 |
| 4-Amino-2sulfobenzoic acid | $\mathrm{C}_{7} \mathrm{H}_{7} \mathrm{NO}_{5} \mathrm{~S}$ | 217.2 | 3477 | 1.709 | 445.7 | 187 |
| 4-iodophenol | $\mathrm{C}_{6} \mathrm{H}_{5} \mathrm{IO}$ | 220.0 | 3628 | 1.857 | 329.2 | 93 |
| 5-Aminosalicylic acid | $\mathrm{C}_{7} \mathrm{H}_{7} \mathrm{NO}_{3}$ | 153.1 | 840 | 1.570 | 403.9 | 280 |
| 5-Bromo-2,4dihydroxybenzoic acid | $\mathrm{C}_{7} \mathrm{H}_{5} \mathrm{BrO}_{4}$ | 233.0 | 2747 | 2.026 | 436.7 | 209 |
| Acetaminophen | $\mathrm{C}_{8} \mathrm{H}_{9} \mathrm{NO}_{2}$ | 151.2 | 4114 | 1.293 | 420 | 170 |
| Acetamiprid | $\mathrm{C}_{10} \mathrm{H}_{11} \mathrm{ClN}_{4}$ | 222.7 | 3623 | 1.330 | 352 | 99 |
| Acetanilide | $\mathrm{C}_{8} \mathrm{H}_{9} \mathrm{NO}$ | 135.2 | 3806 | 1.121 | 304 | 115 |
| Acetazolamide | $\mathrm{C}_{4} \mathrm{H}_{6} \mathrm{~N}_{4} \mathrm{O}_{3} \mathrm{~S}_{2}$ | 222.2 | 2991 | 1.744 | 514 | 258 |
| Acetochlor | $\mathrm{C}_{14} \mathrm{H}_{20} \mathrm{ClNO}_{2}$ | 269.8 | 2348 | 1.107 | 172 | 1 |
| Acetylacetone | $\mathrm{C}_{5} \mathrm{H}_{8} \mathrm{O}_{2}$ | 100.1 | 5221 | 0.975 | 140 | -23 |
| Acibenzolar-Smethyl | $\mathrm{C}_{8} \mathrm{H}_{6} \mathrm{~N}_{2} \mathrm{OS}_{2}$ | 210.3 | 887 | 1.500 | 267 | 133 |
| Acrylamide | $\mathrm{C}_{3} \mathrm{H}_{5} \mathrm{NO}$ | 71.1 | 5806 | 1.120 | 125 | 84 |
| Acylonitrile | $\mathrm{C}_{3} \mathrm{H}_{3} \mathrm{~N}$ | 53.1 | 4872 | 0.801 | 77 | -83 |
| Adenine | $\mathrm{C}_{5} \mathrm{H}_{5} \mathrm{~N}_{5}$ | 135.1 | 3013 | 1.612 | 553.5 | 360 |
| Adenosine | $\mathrm{C}_{10} \mathrm{H}_{13} \mathrm{~N}_{5} \mathrm{O}_{4}$ | 267.2 | 5100 | 2.080 | 676.3 | 234 |
| Adipic acid | $\mathrm{C}_{6} \mathrm{H}_{10} \mathrm{O}_{4}$ | 146.1 | 4414 | 1.360 | 337.5 | 152 |
| Aldicarb | $\mathrm{C}_{7} \mathrm{H}_{14} \mathrm{~N}_{2} \mathrm{O}_{2} \mathrm{~S}$ | 190.3 | 3780 | 1.195 | 225 | 100 |
| Allobarbital | $\mathrm{C}_{10} \mathrm{H}_{12} \mathrm{~N}_{2} \mathrm{O}_{3}$ | 208.2 | 3258 | 1.100 | 468.8 | 172 |
| Allopurinol | $\mathrm{C}_{5} \mathrm{H}_{4} \mathrm{~N}_{4} \mathrm{O}$ | 136.1 | 569 | 1.890 | 423.3 | 350 |
| Alochlor | $\mathrm{C}_{14} \mathrm{H}_{20} \mathrm{ClNO}_{2}$ | 269.8 | 2380 | 1.133 | 100 | 40 |
| Alphaacetylbutyrolactone | $\mathrm{C}_{6} \mathrm{H}_{8} \mathrm{O}_{3}$ | 128.1 | 5301 | 1.190 | 253 | -12 |
| Alprenolol | $\mathrm{C}_{15} \mathrm{H}_{23} \mathrm{NO}_{2}$ | 249.3 | 2763 | 1.000 | 383.4 | 108 |
| Amantadine | $\mathrm{C}_{10} \mathrm{H}_{17} \mathrm{~N}$ | 151.2 | 3326 | 1.100 | 373 | 206 |
| Amitriptyline | $\mathrm{C}_{20} \mathrm{H}_{23} \mathrm{~N}$ | 277.4 | 892 | 1.100 | 398.2 | 196 |

© 2019 Life Science Informatics Publication All rights reserved Peer review under responsibility of Life Science Informatics Publications

Al-Malah RJLBPCS 2019
www.rjlbpes.com

| NAME | Molecular Formula | MW (g/mol) | Aq. Sol (mg/L) | Density $\left(\mathrm{g} / \mathrm{cm}^{3}\right)$ | $\begin{aligned} & \mathbf{B P} \\ & \left({ }^{\circ} \mathbf{C}\right) \end{aligned}$ | $\begin{aligned} & \text { MP } \\ & \left({ }^{\circ} \mathbf{C}\right) \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Amobarbital | $\mathrm{C}_{11} \mathrm{H}_{18} \mathrm{~N}_{2} \mathrm{O}_{3}$ | 226.3 | 2780 | 1.138 | 367.9 | 157 |
| Ancymidol | $\mathrm{C}_{15} \mathrm{H}_{16} \mathrm{~N}_{2} \mathrm{O}_{2}$ | 256.3 | 2813 | 1.300 | 442.2 | 110 |
| Aniline | $\mathrm{C}_{6} \mathrm{H}_{7} \mathrm{~N}$ | 93.1 | 4556 | 1.020 | 184.1 | -6 |
| Antipyrine | $\mathrm{C}_{11} \mathrm{H}_{12} \mathrm{~N}_{2} \mathrm{O}$ | 188.2 | 5665 | 1.190 | 319 | 114 |
| ANTU( $\alpha$ - <br> Naphthylthiourea) | $\mathrm{C}_{11} \mathrm{H}_{10} \mathrm{~N}_{2} \mathrm{~S}$ | 202.3 | 2778 | 1.333 | 377.6 | 188 |
| Arabinose | $\mathrm{C}_{5} \mathrm{H}_{10} \mathrm{O}_{5}$ | 150.1 | 5698 | 1.585 | 333.2 | 158 |
| Ascorbic acid | $\mathrm{C}_{6} \mathrm{H}_{8} \mathrm{O}_{6}$ | 176.1 | 5522 | 1.694 | 553 | 191 |
| Aspartic acid | $\mathrm{C}_{4} \mathrm{H}_{7} \mathrm{NO}_{4}$ | 133.1 | 3912 | 1.700 | 324 | 270 |
| Aspirin | $\mathrm{C}_{9} \mathrm{H}_{8} \mathrm{O}_{4}$ | 180.2 | 3663 | 1.400 | 321 | 135 |
| Asulam | $\mathrm{C}_{8} \mathrm{H}_{10} \mathrm{~N}_{2} \mathrm{O}_{4} \mathrm{~S}$ | 230.2 | 3699 | 1.460 | 382.3 | 144 |
| Atropine | $\mathrm{C}_{17} \mathrm{H}_{23} \mathrm{NO}_{3}$ | 289.4 | 3459 | 1.200 | 429.8 | 115 |
| Azathioprine | $\mathrm{C}_{9} \mathrm{H}_{7} \mathrm{~N}_{7} \mathrm{O}_{2} \mathrm{~S}$ | 277.3 | 2235 | 1.900 | 685.7 | 243 |
| Azintamide | $\mathrm{C}_{10} \mathrm{H}_{14} \mathrm{ClN}_{3} \mathrm{OS}$ | 259.8 | 3699 | 1.270 | 435.3 | 97 |
| Baclofen | $\mathrm{C}_{10} \mathrm{H}_{12} \mathrm{ClNO}_{2}$ | 213.7 | 4549 | 1.300 | 364.3 | 207 |
| Badische acid | $\mathrm{C}_{10} \mathrm{H}_{9} \mathrm{NO}_{3} \mathrm{~S}$ | 223.2 | 2775 | 1.500 | 434.2 | 173 |
| Barban | $\mathrm{C}_{11} \mathrm{H}_{9} \mathrm{Cl}_{2} \mathrm{NO}_{2}$ | 258.1 | 1042 | 1.403 | 224 | 75 |
| Barbital | $\mathrm{C}_{8} \mathrm{H}_{12} \mathrm{~N}_{2} \mathrm{O}_{3}$ | 184.2 | 3873 | 1.100 | 507.8 | 190 |
| Bendiocarb | $\mathrm{C}_{11} \mathrm{H}_{13} \mathrm{NO}_{4}$ | 223.2 | 2415 | 1.250 | 299 | 130 |
| Benzidine | $\mathrm{C}_{12} \mathrm{H}_{12} \mathrm{~N}_{2}$ | 184.2 | 2505 | 1.250 | 401 | 127 |
| Benzocaine | $\mathrm{C}_{9} \mathrm{H}_{11} \mathrm{NO}_{2}$ | 165.2 | 2898 | 1.170 | 310 | 89 |
| Benzoic acid | $\mathrm{C}_{7} \mathrm{H}_{6} \mathrm{O}_{2}$ | 122.1 | 3350 | 1.266 | 249.2 | 122 |
| Benzylimidazole | $\mathrm{C}_{10} \mathrm{H}_{10} \mathrm{~N}_{2}$ | 158.2 | 2942 | 1.220 | 310 | 70 |
| Bromogramine | $\mathrm{C}_{11} \mathrm{H}_{13} \mathrm{BrN}_{2}$ | 253.1 | 1348 | 1.500 | 346.9 | 160 |
| Bronidox | $\mathrm{C}_{4} \mathrm{H}_{6} \mathrm{BrNO}_{4}$ | 212.0 | 5737 | 1.830 | 280 | 60 |
| Bupivacaine | $\mathrm{C}_{18} \mathrm{H}_{28} \mathrm{~N}_{2} \mathrm{O}$ | 288.4 | 2236 | 1.000 | 423.4 | 107 |
| Butamben | $\mathrm{C}_{11} \mathrm{H}_{15} \mathrm{NO}_{2}$ | 193.2 | 182 | 1.078 | 303.6 | 58 |
| Butylparaben | $\mathrm{C}_{11} \mathrm{H}_{14} \mathrm{O}_{3}$ | 194.2 | 198 | 1.280 | 369.2 | 68 |
| Capric acid | $\mathrm{C}_{10} \mathrm{H}_{20} \mathrm{O}_{2}$ | 172.3 | 1791 | 0.900 | 269 | 31 |
| Caproic acid | $\mathrm{C}_{6} \mathrm{H}_{12} \mathrm{O}_{2}$ | 116.2 | 4012 | 0.930 | 203 | -3 |
| Carbamazepine | $\mathrm{C}_{15} \mathrm{H}_{12} \mathrm{~N}_{2} \mathrm{O}$ | 236.3 | 150 | 1.296 | 411 | 191 |
| Carbofuran | $\mathrm{C}_{12} \mathrm{H}_{15} \mathrm{NO}_{3}$ | 221.2 | 2505 | 1.180 | 200 | 148 |
| Carfentrazone-ethyl | $\mathrm{C}_{15} \mathrm{H}_{14} \mathrm{Cl}_{2} \mathrm{~F}_{3} \mathrm{~N}_{3} \mathrm{O}_{3}$ | 412.2 | 1343 | 1.457 | 352.5 | -22 |
| Carisoprodol | $\mathrm{C}_{12} \mathrm{H}_{24} \mathrm{~N}_{2} \mathrm{O}_{4}$ | 260.2 | 2477 | 1.100 | 423 | 92 |
| Carmustine | $\mathrm{C}_{5} \mathrm{H}_{9} \mathrm{Cl}_{2} \mathrm{~N}_{3} \mathrm{O}_{2}$ | 214.0 | 3602 | 1.500 | 309.5 | 31 |
| Carnosine | $\mathrm{C}_{9} \mathrm{H}_{14} \mathrm{~N}_{4} \mathrm{O}_{3}$ | 226.2 | 4914 | 1.400 | 656 | 253 |
| Carprofen | $\mathrm{C}_{15} \mathrm{H}_{12} \mathrm{ClNO}_{2}$ | 273.7 | 740 | 1.400 | 509 | 197 |
| Carvedilol | $\mathrm{C}_{24} \mathrm{H}_{26} \mathrm{~N}_{2} \mathrm{O}_{4}$ | 406.5 | 1354 | 1.300 | 655 | 114 |
| Cephalothin | $\mathrm{C}_{16} \mathrm{H}_{16} \mathrm{~N}_{2} \mathrm{O}_{6} \mathrm{~S}_{2}$ | 396.4 | 2660 | 1.600 | 757.2 | 160 |
| Chloramphenicol | $\mathrm{C}_{11} \mathrm{H}_{12} \mathrm{Cl}_{2} \mathrm{~N}_{2} \mathrm{O}_{5}$ | 323.1 | 3186 | 1.547 | 644.9 | 151 |
| Chlorpheniramine | $\mathrm{C}_{16} \mathrm{H}_{19} \mathrm{ClN}_{2}$ | 274.8 | 2771 | 1.100 | 142 | 132 |
| Chlorpromazine | $\mathrm{C}_{17} \mathrm{H}_{19} \mathrm{ClN}_{2} \mathrm{~S}$ | 318.9 | 431 | 1.200 | 450 | 57 |
| Chlorthalidone | $\mathrm{C}_{14} \mathrm{H}_{11} \mathrm{ClN}_{2} \mathrm{O}_{4} \mathrm{~S}$ | 338.8 | 120 | 1.600 | 559.8 | 225 |
| Chlorzoxazone | $\mathrm{C}_{7} \mathrm{H}_{4} \mathrm{ClNO}_{2}$ | 169.6 | 1000 | 1.486 | 336 | 192 |
| Cimetidine | $\mathrm{C}_{10} \mathrm{H}_{16} \mathrm{~N}_{6} \mathrm{~S}$ | 252.3 | 3710 | 1.300 | 488 | 142 |

© 2019 Life Science Informatics Publication All rights reserved Peer review under responsibility of Life Science Informatics Publications 2019 Nov - Dec RJLBPCS 5(6) Page No. 25
www.rjlbpcs.com
Life Science Informatics Publications

| NAME | Molecular Formula | MW (g/mol) | Aq. Sol (mg/L) | Density $\left(\mathrm{g} / \mathrm{cm}^{3}\right)$ | BP <br> $\left({ }^{\circ} \mathrm{C}\right)$ | $\begin{aligned} & \text { MP } \\ & \left({ }^{\circ} \mathbf{C}\right) \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Ciprofloxacin | $\mathrm{C}_{17} \mathrm{H}_{18} \mathrm{FN}_{3} \mathrm{O}_{3}$ | 331.3 | 1924 | 1.500 | 582 | 255 |
| Corticosterone | $\mathrm{C}_{21} \mathrm{H}_{30} \mathrm{O}_{4}$ | 346.5 | 199 | 1.200 | 500 | 145 |
| Cortisone | $\mathrm{C}_{21} \mathrm{H}_{28} \mathrm{O}_{5}$ | 360.4 | 255 | 1.300 | 534 | 222 |
| Crotonic Acid | $\mathrm{C}_{4} \mathrm{H}_{6} \mathrm{O}_{2}$ | 86.1 | 4934 | 1.027 | 185 | 71 |
| Cumic Acid | $\mathrm{C}_{10} \mathrm{H}_{12} \mathrm{O}_{2}$ | 164.2 | 2179 | 1.100 | 271.8 | 118 |
| Cyanazine | $\mathrm{C}_{9} \mathrm{H}_{13} \mathrm{ClN}_{6}$ | 240.7 | 2233 | 1.300 | 442.4 | 167 |
| Cyanuric Acid | $\mathrm{C}_{3} \mathrm{H}_{3} \mathrm{~N}_{3} \mathrm{O}_{3}$ | 129.1 | 3301 | 2.000 | 793.4 | 320 |
| Cyclizine | $\mathrm{C}_{18} \mathrm{H}_{22} \mathrm{~N}_{2}$ | 266.4 | 3000 | 1.100 | 363.7 | 105 |
| Cyclobarbital | $\mathrm{C}_{12} \mathrm{H}_{16} \mathrm{~N}_{2} \mathrm{O}_{3}$ | 236.3 | 3204 | 1.200 | 549 | 172 |
| Cycloleucine | $\mathrm{C}_{6} \mathrm{H}_{11} \mathrm{NO}_{2}$ | 129.2 | 4698 | 1.200 | 420 | 328 |
| Cyproconazole | $\mathrm{C}_{15} \mathrm{H}_{18} \mathrm{ClN}_{3} \mathrm{O}$ | 291.8 | 2146 | 1.300 | 375 | 106 |
| Cyprodinil | $\mathrm{C}_{14} \mathrm{H}_{15} \mathrm{~N}_{3}$ | 225.3 | 1114 | 1.200 | 406 | 76 |
| Cystine | $\mathrm{C}_{6} \mathrm{H}_{12} \mathrm{~N}_{2} \mathrm{O}_{4} \mathrm{~S}_{2}$ | 240.3 | 2049 | 1.600 | 387 | 246 |
| Cytosine | $\mathrm{C}_{4} \mathrm{H}_{5} \mathrm{~N}_{3} \mathrm{O}$ | 111.1 | 7543 | 1.600 | 283.2 | 91 |
| Danofloxacin | $\mathrm{C}_{19} \mathrm{H}_{20} \mathrm{FN}_{3} \mathrm{O}_{3}$ | 357.4 | 2654 | 1.500 | 569 | 317 |
| Dapsone | $\mathrm{C}_{12} \mathrm{H}_{12} \mathrm{~N}_{2} \mathrm{O}_{2} \mathrm{~S}$ | 248.3 | 150 | 1.400 | 475 | 175 |
| Dehydroacetic Acid | $\mathrm{C}_{8} \mathrm{H}_{8} \mathrm{O}_{4}$ | 168.1 | 2839 | 1.300 | 270 | 111 |
| Deoxycorticosterone | $\mathrm{C}_{21} \mathrm{H}_{30} \mathrm{O}_{3}$ | 330.5 | 145 | 1.200 | 456 | 141 |
| Deprenyl | $\mathrm{C}_{13} \mathrm{H}_{17} \mathrm{~N}$ | 187.3 | 2760 | 1.000 | 272.5 | 141 |
| Desipramine | $\mathrm{C}_{18} \mathrm{H}_{22} \mathrm{~N}_{2}$ | 266.4 | 1799 | 1.000 | 407 | 216 |
| Dexamethasone | $\mathrm{C}_{22} \mathrm{H}_{29} \mathrm{FO}_{5}$ | 392.5 | 1949 | 1.300 | 538 | 263 |
| Diazepam | $\mathrm{C}_{16} \mathrm{H}_{13} \mathrm{ClN}_{2} \mathrm{O}$ | 284.7 | 1699 | 1.300 | 497.4 | 128 |
| Diazoxide | $\mathrm{C}_{8} \mathrm{H}_{7} \mathrm{ClN}_{2} \mathrm{O}_{2} \mathrm{~S}$ | 230.7 | 2000 | 1.600 | 415 | 330 |
| Dicamba | $\mathrm{C}_{8} \mathrm{H}_{6} \mathrm{Cl}_{2} \mathrm{O}_{3}$ | 221.0 | 2920 | 1.500 | 326 | 115 |
| Dichlobenil | $\mathrm{C}_{7} \mathrm{H}_{3} \mathrm{Cl}_{2} \mathrm{~N}$ | 172.0 | 1327 | 1.309 | 270 | 145 |
| Difenoconazole | $\mathrm{C}_{19} \mathrm{H}_{17} \mathrm{Cl}_{2} \mathrm{~N}_{3} \mathrm{O}_{3}$ | 406.3 | 1177 | 1.400 | 220 | 76 |
| Difloxacin | $\mathrm{C}_{21} \mathrm{H}_{19} \mathrm{~F}_{2} \mathrm{~N}_{3} \mathrm{O}_{3}$ | 399.4 | 2000 | 1.400 | 595 | 322 |
| Digallic Acid | $\mathrm{C}_{14} \mathrm{H}_{10} \mathrm{O}_{9}$ | 322.2 | 2699 | 1.800 | 565 | 268 |
| Diltiazem | $\mathrm{C}_{22} \mathrm{H}_{26} \mathrm{~N}_{2} \mathrm{O}_{4} \mathrm{~S}$ | 414.5 | 2458 | 1.300 | 594 | 210 |
| Dimethenamid | $\mathrm{C}_{12} \mathrm{H}_{18} \mathrm{ClNO}_{2} \mathrm{~S}$ | 275.8 | 3079 | 1.187 | 383 | 139 |
| Dimethirimol | $\mathrm{C}_{11} \mathrm{H}_{19} \mathrm{~N}_{3} \mathrm{O}$ | 209.3 | 3079 | 1.100 | 350 | 102 |
| Diphenydramine | $\mathrm{C}_{17} \mathrm{H}_{21} \mathrm{NO}$ | 255.4 | 2461 | 1.000 | 343.7 | 168 |
| Diphenylhydantoin (Phenytoin) | $\mathrm{C}_{15} \mathrm{H}_{12} \mathrm{~N}_{2} \mathrm{O}_{2}$ | 252.3 | 1544 | 1.300 | 464 | 295 |
| DL-Camphor | $\mathrm{C}_{10} \mathrm{H}_{16} \mathrm{O}$ | 152.2 | 1600 | 0.992 | 204 | 180 |
| Enrofloxacin (Baytril) | $\mathrm{C}_{19} \mathrm{H}_{22} \mathrm{FN}_{3} \mathrm{O}_{3}$ | 359.4 | 2375 | 1.400 | 560 | 221 |
| EPTC | $\mathrm{C}_{9} \mathrm{H}_{19} \mathrm{NOS}$ | 189.3 | 2574 | 0.955 | 232 | 60 |
| Equilin | $\mathrm{C}_{18} \mathrm{H}_{20} \mathrm{O}_{2}$ | 268.3 | 150 | 1.200 | 459 | 239 |
| Ethinamate | $\mathrm{C}_{9} \mathrm{H}_{13} \mathrm{NO}_{2}$ | 167.2 | 3398 | 1.100 | 237.3 | 96 |
| Ethirimol | $\mathrm{C}_{11} \mathrm{H}_{19} \mathrm{~N}_{3} \mathrm{O}$ | 209.3 | 2301 | 1.100 | 365.7 | 160 |
| Ethofumesate | $\mathrm{C}_{13} \mathrm{H}_{18} \mathrm{O}_{5} \mathrm{~S}$ | 286.3 | 1699 | 1.300 | 409.1 | 71 |
| Ethohexadiol | $\mathrm{C}_{8} \mathrm{H}_{18} \mathrm{O}_{2}$ | 146.2 | 4623 | 0.900 | 244 | -40 |
| Ethoprop | $\mathrm{C}_{8} \mathrm{H}_{19} \mathrm{O}_{2} \mathrm{PSS}_{2}$ | 242.3 | 2875 | 1.100 | 310.2 | -13 |
| Ethylparaben | $\mathrm{C}_{9} \mathrm{H}_{10} \mathrm{O}_{3}$ | 166.2 | 885 | 1.171 | 297.5 | 117 |

(C) 2019 Life Science Informatics Publication All rights reserved Peer review under responsibility of Life Science Informatics Publications

Al-Malah RJLBPCS 2019
www.rjlbpcs.com

| RJLBPCS 2019 www.rjlbpcs.com |  |  | Life Science Informatics Publications |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| NAME | Molecular <br> Formula | MW (g/mol) | Aq. Sol (mg/L) | Density $\left(\mathrm{g} / \mathrm{cm}^{3}\right)$ | $\begin{array}{\|l\|} \hline \mathbf{B P} \\ \left({ }^{\circ} \mathbf{C}\right) \\ \hline \end{array}$ | $\begin{array}{\|l\|} \hline \mathbf{M P} \\ \left({ }^{\circ} \mathbf{C}\right) \\ \hline \end{array}$ |
| Famotidine(Pepcid) | $\mathrm{C}_{8} \mathrm{H}_{15} \mathrm{~N}_{7} \mathrm{O}_{2} \mathrm{~S}_{3}$ | 337.5 | 2881 | 1.800 | 662.4 | 163 |
| Fenbufen | $\mathrm{C}_{16} \mathrm{H}_{14} \mathrm{O}_{3}$ | 254.3 | 344 | 1.157 | 470.2 | 186 |
| Fenoprofen | $\mathrm{C}_{15} \mathrm{H}_{14} \mathrm{O}_{3}$ | 242.3 | 1681 | 1.200 | 381.3 | 169 |
| Fenpiclonil | $\mathrm{C}_{11} \mathrm{H}_{6} \mathrm{Cl}_{2} \mathrm{~N}_{2}$ | 237.1 | 682 | 1.500 | 437.5 | 150 |
| Fludrocortisone | $\mathrm{C}_{21} \mathrm{H}_{29} \mathrm{FO}_{5}$ | 380.4 | 2146 | 1.300 | 564.7 | 261 |
| Flufenacet | $\mathrm{C}_{14} \mathrm{H}_{13} \mathrm{~F}_{4} \mathrm{~N}_{3} \mathrm{O}_{2} \mathrm{~S}$ | 363.3 | 1748 | 1.312 | 401.5 | 79 |
| Flumequine | $\mathrm{C}_{14} \mathrm{H}_{12} \mathrm{FNO}_{3}$ | 261.2 | 1681 | 1.500 | 439.7 | 254 |
| Flumioxazin | $\mathrm{C}_{19} \mathrm{H}_{15} \mathrm{FN}_{2} \mathrm{O}_{4}$ | 354.3 | 253 | 1.500 | 644.4 | 204 |
| Flurbiprofen | $\mathrm{C}_{15} \mathrm{H}_{13} \mathrm{FO}_{2}$ | 244.3 | 1235 | 1.200 | 162.4 | 110 |
| Fluspirilene | $\mathrm{C}_{29} \mathrm{H}_{31} \mathrm{~F}_{2} \mathrm{~N}_{3} \mathrm{O}$ | 475.6 | 1000 | 1.300 | 668.9 | 189 |
| Fumaric acid | $\mathrm{C}_{4} \mathrm{H}_{4} \mathrm{O}_{4}$ | 116.1 | 3845 | 1.500 | 355 | 287 |
| Furazolidone | $\mathrm{C}_{8} \mathrm{H}_{7} \mathrm{~N}_{3} \mathrm{O}_{5}$ | 225.2 | 1603 | 1.700 | 353.4 | 255 |
| Ganciclovir | $\mathrm{C}_{9} \mathrm{H}_{13} \mathrm{~N}_{5} \mathrm{O}_{4}$ | 255.2 | 3633 | 1.360 | 398.5 | 250 |
| Glipizide | $\mathrm{C}_{21} \mathrm{H}_{27} \mathrm{~N}_{5} \mathrm{O}_{4} \mathrm{~S}$ | 445.5 | 161 | 1.300 | 689 | 208 |
| Gluconolactone | $\mathrm{C}_{6} \mathrm{H}_{10} \mathrm{O}_{6}$ | 178.1 | 5770 | 1.700 | 446 | 155 |
| Glutamic acid | $\mathrm{C}_{5} \mathrm{H}_{9} \mathrm{NO}_{4}$ | 147.1 | 3933 | 1.538 | 333.8 | 205 |
| Glycine | $\mathrm{C}_{2} \mathrm{H}_{5} \mathrm{NO}_{2}$ | 75.1 | 5396 | 1.600 | 240.9 | 240 |
| Glyphosate | $\mathrm{C}_{3} \mathrm{H}_{8} \mathrm{NO}_{5} \mathrm{P}$ | 169.1 | 4079 | 1.704 | 465.8 | 215 |
| Guaifenesin | $\mathrm{C}_{10} \mathrm{H}_{14} \mathrm{O}_{4}$ | 198.2 | 4698 | 1.200 | 215 | 80 |
| Guanine | $\mathrm{C}_{5} \mathrm{H}_{5} \mathrm{~N}_{5} \mathrm{O}$ | 151.1 | 748 | 2.200 | 493.8 | 300 |
| Haloperidol | $\mathrm{C}_{21} \mathrm{H}_{23} \mathrm{ClFNO}_{2}$ | 375.9 | 1147 | 1.200 | 529 | 149 |
| Heptabarbital | $\mathrm{C}_{13} \mathrm{H}_{18} \mathrm{~N}_{2} \mathrm{O}_{3}$ | 250.3 | 2398 | 1.300 | 427.4 | 174 |
| Hexazinone | $\mathrm{C}_{12} \mathrm{H}_{20} \mathrm{~N}_{4} \mathrm{O}_{2}$ | 252.3 | 4519 | 1.300 | 332.8 | 116 |
| Hexobarbital | $\mathrm{C}_{12} \mathrm{H}_{16} \mathrm{~N}_{2} \mathrm{O}_{3}$ | 236.3 | 2699 | 1.200 | 530.7 | 146 |
| Histidine | $\mathrm{C}_{6} \mathrm{H}_{9} \mathrm{~N}_{3} \mathrm{O}_{2}$ | 155.2 | 4658 | 1.400 | 458.9 | 282 |
| Hydrochlorothiazide | $\mathrm{C}_{7} \mathrm{H}_{8} \mathrm{ClN}_{3} \mathrm{O}_{4} \mathrm{~S}_{2}$ | 297.7 | 722 | 1.700 | 577 | 274 |
| Hydrocortisone | $\mathrm{C}_{21} \mathrm{H}_{30} \mathrm{O}_{5}$ | 362.5 | 2505 | 1.081 | 414.1 | 218 |
| Hydroflumethiazide | $\mathrm{C}_{8} \mathrm{H}_{8} \mathrm{~F}_{3} \mathrm{~N}_{3} \mathrm{O}_{4} \mathrm{~S}_{2}$ | 331.3 | 2516 | 1.700 | 531.6 | 272 |
| Hydroquinone | $\mathrm{C}_{6} \mathrm{H}_{6} \mathrm{O}_{2}$ | 110.1 | 4857 | 1.300 | 286 | 172 |
| Hydroxyphenamate | $\mathrm{C}_{11} \mathrm{H}_{15} \mathrm{NO}_{3}$ | 209.2 | 4397 | 1.200 | 415.4 | 55 |
| Hydroxyproline | $\mathrm{C}_{5} \mathrm{H}_{9} \mathrm{NO}_{3}$ | 131.1 | 5557 | 1.400 | 355.2 | 273 |
| Hymexazol | $\mathrm{C}_{4} \mathrm{H}_{5} \mathrm{NO}_{2}$ | 99.1 | 4929 | 1.200 | 363.6 | 86 |
| Hyoscyamine | $\mathrm{C}_{17} \mathrm{H}_{23} \mathrm{NO}_{3}$ | 289.4 | 3560 | 1.200 | 429.8 | 108 |
| Ibuprofen | $\mathrm{C}_{13} \mathrm{H}_{18} \mathrm{O}_{2}$ | 206.3 | 1716 | 1.030 | 364.8 | 76 |
| Idoxuridine | $\mathrm{C}_{9} \mathrm{H}_{11} \mathrm{IN}_{2} \mathrm{O}_{5}$ | 354.2 | 3301 | 2.100 | 573.0 | 191 |
| Imazapyr | $\mathrm{C}_{13} \mathrm{H}_{15} \mathrm{~N}_{3} \mathrm{O}_{3}$ | 261.3 | 4053 | 1.300 | 425.1 | 171 |
| Imazaquin | $\mathrm{C}_{17} \mathrm{H}_{17} \mathrm{~N}_{3} \mathrm{O}_{3}$ | 311.3 | 1955 | 1.400 | 609.3 | 221 |
| Imazethapyr | $\mathrm{C}_{15} \mathrm{H}_{19} \mathrm{~N}_{3} \mathrm{O}_{3}$ | 289.3 | 3146 | 1.300 | 446.8 | 171 |
| Indoprofen | $\mathrm{C}_{17} \mathrm{H}_{15} \mathrm{NO}_{3}$ | 281.3 | 128 | 1.300 | 511.3 | 213 |
| Iridomyrmecin | $\mathrm{C}_{10} \mathrm{H}_{16} \mathrm{O}_{2}$ | 168.2 | 3301 | 1.000 | 270.5 | 60 |
| Isoflurophate | $\mathrm{C}_{6} \mathrm{H}_{14} \mathrm{FO}_{3} \mathrm{P}$ | 184.1 | 4187 | 1.060 | 183 | -82 |
| Isoleucine | $\mathrm{C}_{6} \mathrm{H}_{13} \mathrm{NO}_{2}$ | 131.2 | 4536 | 1.000 | 408.1 | 268 |
| Isoniazid | $\mathrm{C}_{6} \mathrm{H}_{7} \mathrm{~N}_{3} \mathrm{O}$ | 137.1 | 5146 | 1.200 | 329.8 | 171 |
| Isophorone | $\mathrm{C}_{9} \mathrm{H}_{14} \mathrm{O}$ | 138.2 | 4079 | 0.922 | 215 | -8 |
| Ketanserin | $\mathrm{C}_{22} \mathrm{H}_{22} \mathrm{FN}_{3} \mathrm{O}_{3}$ | 395.4 | 1000 | 1.300 | 607.5 | 231 |

© 2019 Life Science Informatics Publication All rights reserved
Peer review under responsibility of Life Science Informatics Publications

Al-Malah RJLBPCS 2019
www.rjlbpcs.com

| NAME | Molecular <br> Formula | MW (g/mol) | Aq. Sol (mg/L) | Density $\left(\mathrm{g} / \mathrm{cm}^{3}\right)$ | $\begin{aligned} & \text { BP } \\ & \left({ }^{\circ} \mathbf{C}\right) \end{aligned}$ | $\begin{aligned} & \text { MP } \\ & \left({ }^{\circ} \mathbf{C}\right) \\ & \hline \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Khellin | $\mathrm{C}_{14} \mathrm{H}_{12} \mathrm{O}_{5}$ | 260.2 | 3017 | 1.300 | 587 | 154 |
| Lindane | $\mathrm{C}_{6} \mathrm{H}_{6} \mathrm{Cl}_{6}$ | 290.8 | 864 | 1.600 | 323.3 | 112 |
| Linuron | $\mathrm{C}_{9} \mathrm{H}_{10} \mathrm{Cl}_{2} \mathrm{~N}_{2} \mathrm{O}_{2}$ | 249.1 | 1876 | 1.490 | 185 | 93 |
| Lomefloxacin | $\mathrm{C}_{17} \mathrm{H}_{19} \mathrm{~F}_{2} \mathrm{~N}_{3} \mathrm{O}_{3}$ | 351.3 | 3212 | 1.300 | 542.7 | 240 |
| Malathion | $\mathrm{C}_{10} \mathrm{H}_{19} \mathrm{O}_{6} \mathrm{PS}_{2}$ | 330.4 | 2159 | 1.300 | 385.1 | 3 |
| Maprotiline | $\mathrm{C}_{20} \mathrm{H}_{23} \mathrm{~N}$ | 277.4 | 748 | 1.100 | 399.6 | 93 |
| Methocarbamol | $\mathrm{C}_{11} \mathrm{H}_{15} \mathrm{NO}_{5}$ | 241.2 | 7200 | 1.300 | 472.5 | 93 |
| Methomyl(Lannate) | $\mathrm{C}_{5} \mathrm{H}_{10} \mathrm{~N}_{2} \mathrm{O}_{2} \mathrm{~S}$ | 162.2 | 4763 | 1.200 | 228 | 78 |
| Methylparaben (Methyl-phydroxybenzoate) | $\mathrm{C}_{8} \mathrm{H}_{8} \mathrm{O}_{3}$ | 152.1 | 2500 | 1.460 | 275 | 131 |
| Metoclopramide | $\mathrm{C}_{14} \mathrm{H}_{22} \mathrm{ClN}_{3} \mathrm{O}_{2}$ | 299.8 | 1914 | 1.200 | 418.7 | 147 |
| Metronidazole | $\mathrm{C}_{6} \mathrm{H}_{9} \mathrm{~N}_{3} \mathrm{O}_{3}$ | 171.1 | 4012 | 1.399 | 301.12 | 159 |
| Miconazole | $\mathrm{C}_{18} \mathrm{H}_{14} \mathrm{Cl}_{4} \mathrm{~N}_{2} \mathrm{O}$ | 416.1 | 544 | 1.400 | 555.1 | 161 |
| Minoxidil | $\mathrm{C}_{9} \mathrm{H}_{15} \mathrm{~N}_{5} \mathrm{O}$ | 209.2 | 2200 | 1.520 | 348.6 | 248 |
| Nadolol | $\mathrm{C}_{17} \mathrm{H}_{27} \mathrm{NO}_{4}$ | 309.4 | 8330 | 1.190 | 526.4 | 125 |
| Nalidixic acid | $\mathrm{C}_{12} \mathrm{H}_{12} \mathrm{~N}_{2} \mathrm{O}_{3}$ | 232.2 | 1756 | 1.224 | 374.4 | 229 |
| Naloxone | $\mathrm{C}_{19} \mathrm{H}_{21} \mathrm{NO}_{4}$ | 327.4 | 2617 | 1.400 | 532.8 | 202 |
| Naproxen | $\mathrm{C}_{14} \mathrm{H}_{14} \mathrm{O}_{3}$ | 230.3 | 863 | 1.200 | 404 | 153 |
| Niflumic acid | $\mathrm{C}_{13} \mathrm{H}_{9} \mathrm{~F}_{3} \mathrm{~N}_{2} \mathrm{O}_{2}$ | 282.2 | 845 | 1.400 | 378 | 203 |
| Nitrofurantoin | $\mathrm{C}_{8} \mathrm{H}_{6} \mathrm{~N}_{4} \mathrm{O}_{5}$ | 238.2 | 2067 | 1.582 | 380.8 | 268 |
| Norfloxacin | $\mathrm{C}_{16} \mathrm{H}_{18} \mathrm{FN}_{3} \mathrm{O}_{3}$ | 319.3 | 2800 | 1.300 | 695.6 | 220 |
| Nortriptyline | $\mathrm{C}_{19} \mathrm{H}_{21} \mathrm{~N}$ | 263.4 | 1398 | 1.100 | 403.4 | 214 |
| Ofloxacin | $\mathrm{C}_{18} \mathrm{H}_{20} \mathrm{FN}_{3} \mathrm{O}_{4}$ | 361.4 | 4292 | 1.500 | 571.5 | 246 |
| Oxytetracycline | $\mathrm{C}_{22} \mathrm{H}_{24} \mathrm{~N}_{2} \mathrm{O}_{9}$ | 460.4 | 2580 | 1.634 | 727.8 | 183 |
| p-Aminobenzoic acid | $\mathrm{C}_{7} \mathrm{H}_{7} \mathrm{NO}_{2}$ | 137.1 | 5390 | 1.374 | 340 | 188 |
| p-Aminosalicylic acid | $\mathrm{C}_{7} \mathrm{H}_{7} \mathrm{NO}_{3}$ | 153.1 | 1690 | 1.490 | 347 | 150 |
| Papaverine | $\mathrm{C}_{20} \mathrm{H}_{21} \mathrm{NO}_{4}$ | 339.4 | 1663 | 1.200 | 483.2 | 147 |
| p-Fluorobenzoic acid | $\mathrm{C}_{7} \mathrm{H}_{5} \mathrm{FO}_{2}$ | 140.1 | 3079 | 1.300 | 253.7 | 183 |
| Phenacetin | $\mathrm{C}_{10} \mathrm{H}_{13} \mathrm{NO}_{2}$ | 179.2 | 766 | 1.000 | 243 | 134 |
| Phenantroline | $\mathrm{C}_{12} \mathrm{H}_{8} \mathrm{~N}_{2}$ | 180.2 | 3638 | 1.300 | 330 | 117 |
| Phenazopyridine | $\mathrm{C}_{11} \mathrm{H}_{11} \mathrm{~N}_{5}$ | 213.2 | 1137 | 1.300 | 277.4 | 139 |
| Phenobarbital | $\mathrm{C}_{12} \mathrm{H}_{12} \mathrm{~N}_{2} \mathrm{O}_{3}$ | 232.2 | 3072 | 1.200 | 568.8 | 175 |
| Phenolphthalein | $\mathrm{C}_{20} \mathrm{H}_{14} \mathrm{O}_{4}$ | 318.3 | 2603 | 1.300 | 558 | 260 |
| Phenylbutazone | $\mathrm{C}_{6} \mathrm{H}_{6} \mathrm{O}_{4}$ | 308.4 | 1098 | 1.200 | 425 | 105 |
| Phenytoin | $\mathrm{C}_{15} \mathrm{H}_{12} \mathrm{~N}_{2} \mathrm{O}_{2}$ | 252.3 | 1412 | 1.300 | 464 | 295 |
| Phthalazine | $\mathrm{C}_{8} \mathrm{H}_{6} \mathrm{~N}_{2}$ | 130.1 | 4698 | 1.200 | 317 | 90 |
| Phthalic acid | $\mathrm{C}_{8} \mathrm{H}_{6} \mathrm{O}_{4}$ | 166.1 | 3730 | 1.593 | 378.3 | 210 |
| Phthalimide | $\mathrm{C}_{8} \mathrm{H}_{5} \mathrm{NO}_{2}$ | 147.1 | 2556 | 1.210 | 366 | 234 |
| p-Hydroxybenzoic Acid | $\mathrm{C}_{7} \mathrm{H}_{6} \mathrm{O}_{3}$ | 138.1 | 3699 | 1.460 | 336 | 215 |
| Picloram | $\mathrm{C}_{6} \mathrm{H}_{3} \mathrm{Cl}_{3} \mathrm{~N}_{2} \mathrm{O}_{2}$ | 241.5 | 2633 | 1.800 | 421 | 209 |
| Picric Acid | $\mathrm{C}_{6} \mathrm{H}_{3} \mathrm{~N}_{3} \mathrm{O}_{7}$ | 229.1 | 4103 | 1.850 | 300 | 122 |
| Pindolol | $\mathrm{C}_{14} \mathrm{H}_{20} \mathrm{~N}_{2} \mathrm{O}_{2}$ | 248.3 | 1602 | 1.200 | 457.1 | 169 |

© 2019 Life Science Informatics Publication All rights reserved
Peer review under responsibility of Life Science Informatics Publications

Al-Malah RJLBPCS 2019
www.rjlbpes.com

| RJLBPCS 2019 www.rjlbpes.com |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| NAME | Molecular Formula | MW (g/mol) | Aq. Sol (mg/L) | Density $\left(\mathrm{g} / \mathrm{cm}^{3}\right)$ | $\begin{aligned} & \mathbf{B P} \\ & \left({ }^{\circ} \mathbf{C}\right) \end{aligned}$ | $\begin{array}{\|l\|} \hline \text { MP } \\ \left({ }^{\circ} \mathbf{C}\right) \\ \hline \end{array}$ |
| Piroxicam | $\mathrm{C}_{15} \mathrm{H}_{13} \mathrm{~N}_{3} \mathrm{O}_{4} \mathrm{~S}$ | 331.3 | 716 | 1.500 | 568.5 | 200 |
| Praziquantel | $\mathrm{C}_{19} \mathrm{H}_{24} \mathrm{~N}_{2} \mathrm{O}_{2}$ | 312.4 | 400 | 1.200 | 544 | 137 |
| Prednisolone | $\mathrm{C}_{21} \mathrm{H}_{28} \mathrm{O}_{5}$ | 360.4 | 223 | 1.300 | 570 | 235 |
| Primidone | $\mathrm{C}_{12} \mathrm{H}_{14} \mathrm{~N}_{2} \mathrm{O}_{2}$ | 218.2 | 500 | 1.200 | 443 | 281 |
| Procaine | $\mathrm{C}_{13} \mathrm{H}_{20} \mathrm{~N}_{2} \mathrm{O}_{2}$ | 236.3 | 3653 | 1.100 | 373.6 | 61 |
| Propranolol | $\mathrm{C}_{16} \mathrm{H}_{21} \mathrm{NO}_{2}$ | 259.3 | 1919 | 1.100 | 434.9 | 96 |
| Propylparaben | $\mathrm{C}_{10} \mathrm{H}_{12} \mathrm{O}_{3}$ | 180.2 | 500 | 1.100 | 294 | 96 |
| Quinidine | $\mathrm{C}_{20} \mathrm{H}_{24} \mathrm{~N}_{2} \mathrm{O}_{2}$ | 324.4 | 140 | 1.200 | 496 | 174 |
| Quinine | $\mathrm{C}_{20} \mathrm{H}_{24} \mathrm{~N}_{2} \mathrm{O}_{2}$ | 324.4 | 2724 | 1.200 | 496 | 177 |
| Ranitidine | $\mathrm{C}_{13} \mathrm{H}_{22} \mathrm{~N}_{4} \mathrm{O}_{3} \mathrm{~S}$ | 314.4 | 2996 | 1.200 | 437.1 | 70 |
| Salicylamide | $\mathrm{C}_{7} \mathrm{H}_{7} \mathrm{NO}_{2}$ | 137.1 | 2060 | 1.300 | 348.5 | 140 |
| Salicylic acid | $\mathrm{C}_{7} \mathrm{H}_{6} \mathrm{O}_{3}$ | 138.1 | 2240 | 1.400 | 373 | 158 |
| Sparfloxacin | $\mathrm{C}_{19} \mathrm{H}_{22} \mathrm{~F}_{2} \mathrm{~N}_{4} \mathrm{O}_{3}$ | 392.4 | 2335 | 1.400 | 640.4 | 265 |
| Strychnine | $\mathrm{C}_{21} \mathrm{H}_{22} \mathrm{~N}_{2} \mathrm{O}_{2}$ | 334.4 | 180 | 1.360 | 560 | 280 |
| Sulfacetamide | $\mathrm{C}_{8} \mathrm{H}_{10} \mathrm{~N}_{2} \mathrm{O}_{3} \mathrm{~S}$ | 214.2 | 8293 | 1.400 | 450 | 183 |
| Sulfamerazine | $\mathrm{C}_{11} \mathrm{H}_{12} \mathrm{~N}_{4} \mathrm{O}_{2} \mathrm{~S}$ | 264.3 | 202 | 1.400 | 519 | 236 |
| Sulfamethazine | $\mathrm{C}_{12} \mathrm{H}_{14} \mathrm{~N}_{4} \mathrm{O}_{2} \mathrm{~S}$ | 278.3 | 2706 | 1.460 | 526 | 176 |
| Sulfamethoxazole | $\mathrm{C}_{10} \mathrm{H}_{11} \mathrm{~N}_{3} \mathrm{O}_{3} \mathrm{~S}$ | 253.3 | 610 | 1.500 | 482 | 171 |
| Sulfanilamide | $\mathrm{C}_{6} \mathrm{H}_{8} \mathrm{~N}_{2} \mathrm{O}_{2} \mathrm{~S}$ | 172.2 | 7500 | 1.400 | 400 | 165 |
| Sulfathiazole | $\mathrm{C}_{9} \mathrm{H}_{9} \mathrm{~N}_{3} \mathrm{O}_{2} \mathrm{~S}_{2}$ | 255.3 | 2718 | 1.600 | 480 | 202 |
| Sulindac | $\mathrm{C}_{20} \mathrm{H}_{17} \mathrm{FO}_{3} \mathrm{~S}$ | 356.4 | 1041 | 1.400 | 582 | 183 |
| Sulpiride | $\mathrm{C}_{15} \mathrm{H}_{23} \mathrm{~N}_{3} \mathrm{O}_{4} \mathrm{~S}$ | 341.4 | 2280 | 1.200 | 530 | 179 |
| Testosterone | $\mathrm{C}_{19} \mathrm{H}_{28} \mathrm{O}_{2}$ | 288.4 | 1390 | 1.100 | 432.9 | 154 |
| Tetracaine | $\mathrm{C}_{15} \mathrm{H}_{24} \mathrm{~N}_{2} \mathrm{O}_{2}$ | 264.4 | 2412 | 1.000 | 389.4 | 149 |
| Tetracycline | $\mathrm{C}_{22} \mathrm{H}_{24} \mathrm{~N}_{2} \mathrm{O}_{8}$ | 444.4 | 2722 | 1.700 | 738.2 | 170 |
| Theobromine | $\mathrm{C}_{7} \mathrm{H}_{8} \mathrm{~N}_{4} \mathrm{O}_{2}$ | 180.2 | 330 | 1.600 | 483.5 | 350 |
| Theophylline | $\mathrm{C}_{7} \mathrm{H}_{8} \mathrm{~N}_{4} \mathrm{O}_{2}$ | 180.2 | 7360 | 1.500 | 454 | 273 |
| Thiamphenicol | $\mathrm{C}_{12} \mathrm{H}_{15} \mathrm{Cl}_{2} \mathrm{NO}_{5} \mathrm{~S}$ | 356.2 | 3560 | 1.500 | 696 | 165 |
| Thionazin | $\mathrm{C}_{8} \mathrm{H}_{13} \mathrm{~N}_{2} \mathrm{O}_{3} \mathrm{PS}$ | 248.2 | 3057 | 1.300 | 307 | -2 |
| Thymine | $\mathrm{C}_{5} \mathrm{H}_{6} \mathrm{~N}_{2} \mathrm{O}_{2}$ | 126.13 | 3820 | 1.200 | 378 | 316 |
| Thymol | $\mathrm{C}_{10} \mathrm{H}_{14} \mathrm{O}$ | 150.2 | 2991 | 0.970 | 233 | 50 |
| Tolmetin | $\mathrm{C}_{15} \mathrm{H}_{15} \mathrm{NO}_{3}$ | 257.3 | 1322 | 1.200 | 483.2 | 156 |
| Trichloromethiazide | $\mathrm{C}_{8} \mathrm{H}_{8} \mathrm{Cl}_{3} \mathrm{~N}_{3} \mathrm{O}_{4} \mathrm{~S}_{2}$ | 380.7 | 2053 | 1.700 | 631.3 | 250 |
| Trimethoprim | $\mathrm{C}_{14} \mathrm{H}_{18} \mathrm{~N}_{4} \mathrm{O}_{3}$ | 290.3 | 2512 | 1.300 | 405 | 201 |
| Trimipramine | $\mathrm{C}_{20} \mathrm{H}_{26} \mathrm{~N}_{2}$ | 294.4 | 681 | 1.000 | 411.8 | 45 |
| Tryptamine | $\mathrm{C}_{10} \mathrm{H}_{12} \mathrm{~N}_{2}$ | 160.2 | 1903 | 1.200 | 378.8 | 115 |
| Uracil | $\mathrm{C}_{4} \mathrm{H}_{4} \mathrm{~N}_{2} \mathrm{O}_{2}$ | 112.1 | 3600 | 1.300 | 367 | 330 |
| Verapamil | $\mathrm{C}_{27} \mathrm{H}_{38} \mathrm{~N}_{2} \mathrm{O}_{4}$ | 454.6 | 1682 | 1.100 | 586.2 | 228 |
| Warfarin | $\mathrm{C}_{19} \mathrm{H}_{16} \mathrm{O}_{4}$ | 308.3 | 708 | 1.300 | 515.2 | 162 |

Based on molecular properties listed in Table 1, the following additional molecular properties are defined as input arguments for calculation of subsequent molecular properties, where the latter will serve as input (predictor) variables. To demonstrate how such properties are calculated, Table 2 shows molecular properties of 1,6-Cleve's acid.
© 2019 Life Science Informatics Publication All rights reserved Peer review under responsibility of Life Science Informatics Publications 2019 Nov - Dec RJLBPCS 5(6) Page No. 29

Table 2: 1,6-Cleve's acid as an example to demonstrate the definition of additional molecular properties.

| NAME | Molecular <br> Formula | MW | Aq. Sol <br> $(\mathrm{mg} / \mathrm{L})$ | Density <br> $\left(\mathrm{g} / \mathrm{cm}^{3}\right)$ | BP <br> $\left({ }^{\circ} \mathrm{C}\right)$ | MP <br> $\left({ }^{\circ} \mathrm{C}\right)$ |
| :--- | :--- | :--- | ---: | :---: | :---: | :---: |
| 1,6-Cleve's acid | $\mathrm{C}_{10} \mathrm{H}_{9} \mathrm{NO}_{3} \mathrm{~S}$ | 223.3 | 3000 | 1.502 | 434.2 | 173 |

The following equations represent the molecular (or mole-) fraction of each atomic species as part of the molecular constituent of a given drug compound.
$C_{\text {Frac }}=\frac{\text { Number of C Atoms }}{\text { Total Number of Atoms }}=\frac{10}{24}=0.41666$
(1)
$H_{\text {Frac }}=\frac{\text { Number of } H \text { Atoms }}{\text { Total Number of Atoms }}=\frac{9}{24}=0.37500$
(2)
$N_{\text {Frac }}=\frac{\text { Number of } N \text { Atoms }}{\text { Total Number of Atoms }}=\frac{1}{24}=0.04167$
(3)
$O_{\text {Frac }}=\frac{\text { Number of O Atoms }}{\text { Total Number of Atoms }}=\frac{3}{24}=0.12500$
$S_{\text {Frac }}=\frac{\text { Number of S Atoms }}{\text { Total Number of Atoms }}=\frac{1}{24}=0.04167$

Notice that $C_{\text {Frac }}+H_{F r a c}+N_{\text {Frac }}+O_{\text {Frac }}+S_{\text {Frac }}=1$

Table 3 shows the electronegativity value [9] for each atom present in the previous drug molecules.

Table 3: Electronegativity (eV/electron) ${ }^{\boldsymbol{*}}$ of atoms constituting drug molecules.

| Atom | Electronegativity <br> $(\mathbf{e V}) /$ electron |  |  |
| :--- | :--- | :--- | :--- |
| $\mathbf{H}$ | 13.6 | Atom | Electronegativity <br> $(\mathbf{e V}) /$ electron |
| $\mathbf{C}$ | 13.9 | $\mathbf{S}$ | 13.6 |
| $\mathbf{N}$ | 16.9 | $\mathbf{C l}$ | 16.3 |
| $\mathbf{O}$ | 18.6 | $\mathbf{B r}$ | 15.2 |
| $\mathbf{F}$ | 23.3 | $\mathbf{P}$ | 13.4 |

"[9]: Martin Rahm, Tao Zeng, Roald Hoffmann. "Electronegativity Seen as the Ground-State Average Valence Electron Binding Energy". Journal of the American Chemical Society 2019, 141: 342-351.
© 2019 Life Science Informatics Publication All rights reserved

The following equations define the electronegativity contribution for each atomic species, based on its mole-fraction times its atomic electronegativity, as shown in Table 2. For example, let us take 1,6 -Cleve's acid, $\mathrm{C}_{10} \mathrm{H}_{9} \mathrm{NO}_{3} \mathrm{~S}$, then $\mathrm{X}_{\mathrm{C}}$, represents the electronegativity contribution of carbon atoms.
$X_{C}=C_{\text {Frac }} \times E N_{C}=0.41666 \times 13.9=5.7916 \mathrm{eV}$
Other atomic contributions are shown below:
$X_{H}=H_{\text {Frac }} \times E N_{H}=0.37500 \times 13.6=5.1000 \mathrm{eV}$
$X_{\text {Halo }}=$ Halo $_{\text {Frac }} \times E N_{\text {Halogen }}=0 \times E N_{\text {Halo }}=0.0 \mathrm{eV}$
where halo stands for a halogen atom, like $\mathrm{F}, \mathrm{Cl}, \mathrm{Br}$, and I .
$X_{N}=N_{\text {Frac }} \times E N_{N}=0.04167 \times 16.9=0.7042 \mathrm{eV}$
$X_{O}=O_{\text {Frac }} \times E N_{O}=0.12500 \times 18.6=2.3250 \mathrm{eV}$
$X_{P}=P_{\text {Frac }} \times E N_{P}=0 \times 12.8=0.0 \mathrm{eV}$
$X_{S}=S_{\text {Frac }} \times E N_{S}=0.04167 \times 13.6=0.5671 \mathrm{eV}$
$X_{\text {Total }}=\sum_{i=1}^{n} X_{i}=X_{C}+X_{H}+X_{\text {Halo }}+X_{N}+X_{O}+X_{P}+X_{S}$

PolFrac $=\frac{X_{\text {Polar }}}{X_{\text {Total }}}=\frac{\left[X_{F}+X_{O}+X_{N}+X_{C l}+X_{B r}\right]}{X_{\text {non-Polar }}+X_{\text {Polar }}}=\frac{\left[X_{F}+X_{O}+X_{N}+X_{C l}+X_{B r}\right]}{\left[\left\{X_{C}+X_{H}+X_{I}+X_{P}+X_{S}\right\}+\left\{X_{F}+X_{O}+X_{N}+X_{C l}+X_{B r}\right\}\right]}$
Notice that the electronegativities of $\mathrm{F}, \mathrm{O}, \mathrm{N}, \mathrm{Cl}$, and Br atoms have relatively higher values than those of $\mathrm{C}, \mathrm{H}, \mathrm{I}, \mathrm{P}$, and S atoms.
$M_{\text {POL }}\left[\frac{g}{m o l}\right]=($ PoleFrac $) \times M W$
$M_{\text {NPOL }}\left[\frac{g}{\text { mol }}\right]=(1-$ PoleFrac $) \times M W$
MolVol $\left[\frac{L}{\text { mol }}\right]=\frac{M W\left[\frac{g}{m o l}\right]}{\left(\text { Density }\left[\frac{\mathrm{g}}{\left.\mathrm{cm}^{3}\right]}\right] \times \frac{1,000 \mathrm{~cm}^{3}}{L}\right.}$
NPolVol $\left[\frac{L}{m o l}\right]=(1.0-$ PolFrac $) \times$ MolVol
$B P M P R=\left(\frac{\Delta T_{\text {Liquid }}}{\Delta T_{\text {Solid }}}\right)=\left(\frac{T_{B P}-T_{M P}}{T_{M P}-0 K}\right)=\frac{T_{B P}}{T_{M P}}-1=\left\{\frac{B P\left[{ }^{\circ} \mathrm{C}\right]+273}{M P\left[{ }^{[ } \mathrm{C}\right]+273}-1\right\}>0$
The following five linearly independent predictors are included in the analysis:

BPMPR, $X_{P O L}$, PolFrac, $M W_{N P O L}$, and , NPolVol. The aqueous solubility, expressed in $\mathrm{mg} / \mathrm{L}$, is the response variable.

## 3. RESULTS AND DISCUSSION

### 3.1 Raw Data Acquisition

The reason for the normalization step of raw data (i.e., original predictors' data, X ) is simply to make the predictors likely equal in terms of the foothold (weight) and distance (lever) separating each from the response variable. Moreover, if the original predictor has some physical dimensions, then the normalization will transform the predictor into a dimensionless property. For example, molecular properties: $M W_{N P O L}, X_{P O L}$, and NPolVol are all dimensional whereas PolFrac and BPMPR are both dimensionless. ML algorithms deal with predictors from an abstract (i.e., dummy arguments) point of view. Hence, the normalization step is needed in this regard. Of course, the normalized data will scatter between 0 and 1 .

Figure 1 shows MATLAB code, used in all upcoming m-files intended for carrying out subsequent machine learning or optimization step. The code simply fetches molecular properties from Table 1, make data acquisition to define new molecular properties (equations 1 up to 20) and normalize the data for further analysis. Each line of code is preceded by a comment statement to explain what it means.

```
%% RAW MOLECULAR DATA ACQUISITION.
%% The data found in Table 1 will be converted into a numeric 246x5 matrix.
% The matrix represents five molecular predictors of 246 drug molecules.
% Reading # of constituting atoms of a molecule
Cnum=DrugSol4d.Cnum;
Hnum=DrugSol4d.Hnum;
Nnum=DrugSol4d.Nnum;
Onum=DrugSol4d.Onum;
Snum=DrugSol4d.Snum;
Fnum=DrugSol4d.Fnum;
Clnum=DrugSol4d.Clnum;
Brnum=DrugSol4d.Brnum;
Inum=DrugSol4d.Inum;
Pnum=DrugSol4d.Pnum;
% Reading the response variable; i.e., solubility in mg/L.
resp=DrugSol4d.Sol_PPM;
% Reading total number of atoms for each drug molecule.
TotAtom=DrugSol4d.TotAtom;
% Reading the boiling point/melting point ratio.
BPMPR=DrugSol4d.BPMPR;
% BPMPR=normalize(BPMPR,'range');
% Reading the molar volume of a drug molecule.
MolVol=DrugSol4d.MolVol;
% Reading the molecular mass of a drug molecule.
MW=DrugSol4d.MW;
% Defining the electronegativity contribution of each atom in a drug molecule.
XC=13.9*(Cnum./TotAtom);
XH=13.6*(Hnum./TotAtom);
```

Figure 1: MATLAB code to define and normalize molecular and solubility data for further analysis.

### 3.2 P-Value Prediction, Using Least Square Boosted Regression Ensemble

Figure 2 shows that MATLAB's ML fitrensemble function is used. The function: $\mathbf{t M o d e l}=$ fitrensemble(X,Y,'Method','LSBoost', ...) returns optimized hyperparameters of a boosted regression ensemble, using the linear square boost (LSBoost) algorithm and using surrogate splits, based on the predictor, X, and response, Y, data. The additional arguments are meant to further improve the optimization of the resulting model by varying the number of learning cycles, the maximum number of surrogate splits, and the learn rate. Furthermore, the optimization has flexibility to repartition the cross-validation between every iteration. For a better reproducibility, the random seed is set and the expected-improvement-plus acquisition function is used.

```
% For reproducibility, set the random seed.
rng default;
tModel = fitrensemble(X,Y,'Method','LSBoost','Learner',templateTree('Surrogate','on'),...
    'OptimizeHyperparameters', {'NumLearningCycles','MaxNumSplits','LearnRate'},...
    'HyperparameterOptimizationOptions',struct('Repartition',true,...
    'AcquisitionFunctionName','expected-improvement-plus'));
%%predictorImportance function outputs the probability (i.e., how important)for each
predictor.
p = predictorImportance(tModel);
% Sorting the predictors based on their p-values in descending order.
[sortedp,idp]=sort(p,'descend');
figure(3);
% View predictor importance on a bar plot
bar(sortedp)
%Assign labels in light of re-ordering the predictors.
Predictlabel=labels(idp);
% Define the x-axis labels.
xticklabels(Predictlabel);
% Define the y-axis label.
ylabel('Probability');
```

Figure 2: MATLAB code for the ensemble of least square boosted regression, as well as, predicting and presenting the importance of each predictor.

The result of executing both codes shown in figures 1 and 2 is depicted in Figure 3, where it shows, in descending order, the importance of each predictor, expressed in terms of its p-value. Based on the exploited least square algorithm of boosted regression ensemble, MW $W_{N P O L}$ (Eq. 17), NPolVol (Eq. 19) and PolFrac (Eq. 15) are the first three important molecular properties which can explain variation in aqueous solubility.


Figure 3: Prediction of importance for the five predictors, using fitrensemble model.
© 2019 Life Science Informatics Publication All rights reserved

### 3.3 Principle Component Analysis (PCA)

Figure 4 shows the code for applying MATLAB ML Principal Component Analysis (PCA) of X (predictors) data, X , without incorporation of the response variable, Y. The command is:
[pcs, $, \sim, \sim, p e x p, \sim]=\mathbf{p c a}(\mathbf{X})$;
In Eq. (21), out of the six potential output terms, left-hand side of Eq. (21), the following two terms are defined:
pcs: The principal component coefficients, also known as loadings, for the $n \times p$ data matrix, X . $n$ is number of data points and $p$ number of predictors (or parameters). The coefficient matrix, pcs, is $p \times p$. Each column of pcs contains coefficients for one principal component, and the columns are in descending order of component variance.
pexp: The percentage of the total variance explained by each principal component. The concept of principal component analysis in ML simply aims at potential transformation of the original set made of the six predictors into a new set of less number of principal components. For example, in our case study, the original five predictors can be reduced to three principal components (with 97.2 \% accuracy; see Figure 5) or even down to two principal components (with $88.5 \%$ accuracy; see Figure 5). Obviously, the model accuracy decreases with decreasing the number of chosen principal components in the final list.
It should be noticed that the code present in Figure 1 must precede the code in Figure 4, below. It is omitted here to avoid redundancy in coding.

```
%% Method: Feature Transformation with Principal Component Analysis, PCA.
[pcs,~,~,~,pexp,~] = pca(X);
%[coeff,score,latent,tsquared,explained,mu]=pca(X);
% Prepare a window for the upcoming figure.
figure(5);
% Pareto charts display the values in the vector Y as bars drawn in
% descending order. Values in Y must be nonnegative and not include NaNs (not a number).
% Only the first 95% of the cumulative distribution is displayed.
pareto(pexp);
% Prepare x-axis
xticks([1 2 3]);
xticklabels({'PC#1', 'PC#2', 'PC#3'});
% Sort in descending order the percentage of the total variance
% explained by each principal component.
%[sortedp,idp]=sort(pexp,'descend');
% Pareto charts display the values in the vector Y as bars drawn in
% descending order. Values in Y must be nonnegative and not include NaNs.
% Only the first 95% of the cumulative distribution is displayed.
% Prepare a window for the image screen of predictors.
pcssqrd=pcs.^2;
figure(6);
% Plot a colored image screen showing the contribution of predictors to PC.
```

Figure 4: MATLAB code for Principal Component Analysis (PCA) of $\mathbf{X}$ data, using squared principal component coefficients.

The results of executing both codes, shown in figures 1 and 4, are depicted in Figure 5 and 6. Figure 5 shows, in descending order, the first $95 \%$ of the cumulative distribution. In fact, the cumulative distribution amounts to 99.2 \% of the total distribution of X. Notice that the first two principal components, together, account for $86.7 \%$ of the total distribution of X. It is worth mentioning here that each principal component is a cumulative contribution, emanating from the original five predictors. The contribution of each individual predictor can be seen in Figure 6.


Figure 5: Pareto plot for $95 \%$ cumulative distribution of principal components.

As shown in Figure 6, the contribution of each individual predictor is given in the form of colored area. Notice that I found a better approach; instead of taking the absoultute value of the coefficient, I take the square root of each coefficient where the sum of all coeffients will add up to unity for each column of the three principal component columns. The new squared matrix is named pcssqrd $(5 \times 5)$. One may conclude that NPolVol, MWNPOL, and PolFrac are the first

Al-Malah RJLBPCS 2019 three important predictors. The conclusion is in harmony with the previous finding, based on pvalue (Figure 3), using the least square boosted regression ensemble.


Figure 6: The colored image screen for the individual contribution of each original predictor as part of the first, second, and third principal component, PC, using the square value of each coefficient, where the sum adds up to unity for each PC.

### 3.4 Sequential Feature Selection

The following MATLAB code:
ferror $=$ @ (Xtrain,ytrain,Xtest,ytest) nnz(predict(fmodel(Xtrain,ytrain),Xtest) ~= ytest);
creates an anonymous function named ferror that takes four inputs: Xtrain, ytrain, Xtest, and ytest, and returns the number of inaccurate predictions for ytest.
tokeep = sequentialfs(ferror,X,Y,'cv',part,'options',statset('Display','final'));
selects a subset of features from the data matrix X , which best predicts the data in y by sequentially selecting features until there is no improvement in prediction. Rows of X correspond to observations; columns correspond to variables or features. Y is a column vector of response values or class labels for each observation in X. X and Ymust have the same number of rows. ferror is a function handle to a function that defines the criterion used to select features and to determine when to stop. The output tokeep is a logical vector indicating which features (or, predictor columns) are finally chosen. Notice here that there are more than one fmodel to fit into Eq. (22). Any of the following fmodel types can be used:
\% Fit binary decision tree for multiclass classification.
fmodel = @(X,Y) fitcknn(X,Y,"NumNeighbors",20);
© 2019 Life Science Informatics Publication All rights reserved Peer review under responsibility of Life Science Informatics Publications

```
Al-Malah RJLBPCS 2019
temp=templateSVM("KernelFunction","polynomial");
fmodel=@(X,Y)fitcecoc(X,Y,"Learners",temp);
temp=templateSVM("KernelFunction","linear");
fmodel=@(X,Y)fitcecoc(X,Y,"Learners",temp);\%
temp=templateSVM("KernelFunction","gaussian");
fmodel=@(X,Y)fitcecoc(X,Y,"Learners",temp);\%
fmodel = @(X,Y) fitcnb(X,Y,'Distribution','kernel');
Figure 7 shows MATLAB code for sequential feature selection, in addition to the generation of a 3-D plot for aqueous solubility as a function of the first two sequentially selected predictors.
```

```
%% Perform sequential feature selection
```

%% Perform sequential feature selection
% rng('default') puts the settings of the random number generator used
% rng('default') puts the settings of the random number generator used
% by rand, randi, and randn to their default values.
% by rand, randi, and randn to their default values.
rng('default');
rng('default');
% creates an object part that does not partition the data. Both the training
% creates an object part that does not partition the data. Both the training
% set and the test set contain all of the original n observations.
% set and the test set contain all of the original n observations.
part = cvpartition(Y,'resubstitution');
part = cvpartition(Y,'resubstitution');
ti = cputime;
ti = cputime;
% Fit k-nearest neighbor classifier.%
% Fit k-nearest neighbor classifier.%
fmodel = @(X,Y) fitcknn(X,Y,"NumNeighbors",20);
fmodel = @(X,Y) fitcknn(X,Y,"NumNeighbors",20);
ferror = @(Xtrain,ytrain,Xtest,ytest) nnz(predict(fmodel(Xtrain,ytrain),Xtest) ~= ytest);
ferror = @(Xtrain,ytrain,Xtest,ytest) nnz(predict(fmodel(Xtrain,ytrain),Xtest) ~= ytest);
% The output tokeep is a logical vector indicating which features
% The output tokeep is a logical vector indicating which features
% (or, predictor columns) are finally chosen.
% (or, predictor columns) are finally chosen.
tokeep = sequentialfs(ferror,X,Y,'cv',part,...
tokeep = sequentialfs(ferror,X,Y,'cv',part,...
'options',statset('Display','final'));
'options',statset('Display','final'));
elapsetime=cputime-ti;
elapsetime=cputime-ti;
KeptX=X(:,tokeep);
KeptX=X(:,tokeep);
X1=KeptX(:,1);
X1=KeptX(:,1);
X2=KeptX(:,2);
X2=KeptX(:,2);
figure(8);
figure(8);
mylabel=labels(tokeep);
mylabel=labels(tokeep);
plot3(X1,X2,Y,'o');
plot3(X1,X2,Y,'o');
xlabel(mylabel(1,1),'FontSize',14,'FontWeight','bold');
xlabel(mylabel(1,1),'FontSize',14,'FontWeight','bold');
ylabel(mylabel(1,2),'FontSize',14,'FontWeight','bold');
ylabel(mylabel(1,2),'FontSize',14,'FontWeight','bold');
zlabel('Solubility','FontSize',14,'FontWeight','bold');
zlabel('Solubility','FontSize',14,'FontWeight','bold');
grid on;

```
grid on;
```

Figure 7: Sequential feature selection for the five predictors, using sequential feature selection, based on one of the multi-class classifiers.

It is worth mentioning here that the first sequentially selected predictors vary from one fmodel case to another (equations 24 through 28) and also by varying some additional input parameters found in the selected fmodel equation itself. Table 4 shows the results of attempting to first sequentially selecting predictors for each examined case. MWNPOL and PolFrac were first sequentially selected among the five predictors.

Table 4: The first two sequentially selected predictors using different fmodel equations

| \# | fmodel equation <br> number | The first sequentially selected predictors |  | CPU Time |
| :--- | :--- | :--- | :--- | :--- |
| $\mathbf{1}$ | 24 | MWNPOL | PolFrac | 0.4 s |
| $\mathbf{2}$ | $25 \mathrm{a}-25 \mathrm{~b}$ | No sequentially selected predictors | 33.6 minute |  |
| $\mathbf{3}$ | $26 \mathrm{a}-26 \mathrm{~b}$ | No sequentially selected predictors | 32.8 minute |  |
| $\mathbf{4}$ | $27 \mathrm{a}-27 \mathrm{~b}$ | No sequentially selected predictors | 36.1 minute |  |
| $\mathbf{5}$ | 28 | MWNPOL | PolFrac | 23.5 s |

### 3.5 Curve-Fitting: Robust Least Squares

Based on the previously examined ML methods, one can conclude that the following three predictors turn out to be the most important in terms of explaining variation in Y as a function of X: MWNPOL, NPolVol, and PolFrac. Let us consider the solubility as a function of one set at a time and calculate robust least squares regression parameters.

For the sake of simplicity, I will pick up the following pairwise combination of predictors and examine the model goodness of each.

Sol $\left(\frac{m g}{L}\right)=f($ MWNPOL, NPolVol $)$
Sol $\left(\frac{m g}{L}\right)=f($ MWNPOL, PolFrac $)$
Sol $\left(\frac{m g}{L}\right)=f($ NPolVol, PolFrac $)$
Let us examine the three models and see which gives the best fit under robust least squares regression. It is usually assumed that the response errors follow a normal distribution, and that extreme values are rare. Still, extreme values, called outliers, do occur. The main disadvantage of least squares fitting is its sensitivity to outliers. Outliers have a large influence on the fit because squaring the residuals magnifies the effects of these extreme data points. To minimize the influence of outliers, one can fit his/her data using robust least-squares regression. The optimization toolbox provides these two robust regression methods. The Least Absolute Residuals (LAR) method finds a curve that minimizes the absolute difference of the residuals, rather than the squared differences. Therefore, extreme values have a lesser influence on the fit. The other available robust method is the 'bi-square'. This method minimizes a weighted sum of squares, where the weight given to each data point depends on how far the point is from the fitted line. Points near the line get full weight. Points farther from the line get reduced weight or even down to zero weight. This process of elimination can be set by comparing the absolute value of the residual of a given data point to the median absolute deviation of the residuals. The weight will be set to zero if the absolute value of the residual is greater than six times the median, for example. Both methods will work much better than the case when the robust option is disabled, if the predictor data is characterized by a large degree of scatter, which is the case of describing the aqueous solubility of drug-like molecules. Table 5 shows the robust linear least square results using the raw data, presented in Table 1. The weight factor, for each of the three cases, is indicated as $\mathrm{X}_{3}$. To demonstrate the importance of the weight factor, consider the first model, Eq. (29); without the inclusion of the weight factor, $\mathrm{X}_{3}$, as third "variable" in the regression process, the adjusted $\mathrm{R}^{2}$ will drop from 0.9710 down to 0.2215 . So does the case for the second model given by Eq. (30). For the third and last model, Eq. (31), the incorporation of a weight factor did not improve the regression process. In fact, the inclusion of the weight factor, $\mathrm{X}_{3}$, in the third regression case kept the adjusted $\mathrm{R}^{2}$ the same but the root mean square error (RMSE) was drastically blown up from 284.6 up to 3,693.

Table 5: Curve-fitted parameters using the least absolute residual regression with and without a weight factor.

| $\begin{array}{\|l} \hline \text { Eq. } \\ \# \end{array}$ | Selected Predictors $\left(X_{1}, X_{2}\right)$ <br> $X_{3}$ : Weight Factor | Model Parameters: $A q_{\text {Sol }}=\underset{(95 \%}{a \times X_{1}+b \times X_{2}}+C$ | Adjusted <br> R-square: | Root Mean Square Error (RMSE) |
| :---: | :---: | :---: | :---: | :---: |
| 29 | (MWNPOL, NPolVol) $X_{3}$ : PolFrac | $\begin{array}{lr} \hline a=-15 & (-16.38,-13.62) \\ b=4,697 & (3,026,6,367) \\ c=4,870 & (4,776,4,964) \\ \hline \end{array}$ | 0.9710 | 130.0 |
| 30 | (MWNPOL, PolFrac) $X_{3}$ : NPolVol | $\begin{array}{ll} a=-9.533 & (-10.01,-9.058) \\ b=1,175 & (791.1,1,559) \\ c=4,283 & (4,135,4,432) \end{array}$ | 0.9708 | 100.2 |
| 31 | (NPolVol, PolFrac) $X_{3}$ : None | $\begin{aligned} & a=-13,320(-14,060,-12,570) \\ & b=-1,539 \quad(-1,985,-1,093) \\ & c=5,025 \quad(4,836,5,214) \end{aligned}$ | 0.9696 | 284.6 |

3.6 Implementation of Curve-Fitted Model to Candidate Drugs

Let us take the 1,6-Cleve's acid and apply model \#1, presented in Section 3.5.

| NAME | Molecular <br> Formula | MW | Aq. Sol <br> $(\mathbf{m g} / \mathbf{L})$ | Density <br> $\left(\mathbf{g} / \mathbf{c m}^{3}\right)$ | BP <br> $\left({ }^{\circ} \mathbf{C}\right)$ | MP <br> $\left({ }^{\circ} \mathbf{C}\right)$ |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| $\mathbf{1 , 6 - C l e v e ' s ~ a c i d ~}$ | $\mathrm{C}_{10} \mathrm{H}_{9} \mathrm{NO}_{3} \mathrm{~S}$ | 223.3 | 3000 | 1.502 | 434.2 | 173.4 |

$M W=10 \times 12+9 \times 1+1 \times 14+3 \times 16+1 \times 32=223$
$X_{C}=C_{F r a c} \times E N_{C}=\frac{10}{24} \times 13.9=5.792 \mathrm{eV}$
© 2019 Life Science Informatics Publication All rights reserved
$X_{N}=N_{F r a c} \times E N_{N}=\frac{1}{24} \times 16.9=0.7042 \mathrm{eV}$
$X_{O}=O_{F r a c} \times E N_{O}=\frac{3}{24} \times 18.6=2.325 \mathrm{eV}$
$X_{S}=S_{F r a c} \times E N_{S}=\frac{1}{24} \times 13.6=0.5667 \mathrm{eV}$

PolFrac $=\frac{X_{\text {Polar }}}{X_{\text {Total }}}=\frac{\left[X_{N}+X_{O}\right]}{\left[X_{C}+X_{H}+X_{S}+X_{N}+X_{O}\right]}=\frac{3.029}{11.459+3.029}=\frac{3.029}{14.488}=0.2091$
$M W_{N P O L}\left[\frac{g}{m o l}\right]=(1-$ PoleFrac $) \times M W=(1-0.2091) \times 223=176.4 \frac{\mathrm{~g}}{\mathrm{~mol}}$

MolVol $\left[\frac{L}{\mathrm{~mol}}\right]=\frac{M W\left[\frac{\mathrm{~g}}{\mathrm{~mol}}\right]}{\left(\text { Density }\left[\frac{\mathrm{g}}{\mathrm{cm}^{3}}\right]\right) \times \frac{1,000 \mathrm{~cm}^{3}}{L}}=\frac{223}{1.502 \times 1000}=0.14847 \frac{\mathrm{~L}}{\mathrm{~mol}}$

NPolVol $\left[\frac{L}{\mathrm{~mol}}\right]=(1.0-$ PolFrac $) \times$ MolVol $=(0.7909) \times 0.14847=0.11742 \frac{\mathrm{~L}}{\mathrm{~mol}}$

Sol $m_{m / L}=(-15 \times M W N P O L)+(4,697 \times$ NPolVol $)+4,870$
$\operatorname{Sol}_{m g / L}=-2,646+551+4,870=2,775 \mathrm{mg} / \mathrm{L}$

Percent Relative Error $(P R E)=\frac{\mid \text { Measured-Predicted } \mid}{\text { Measured }} \times 100 \%$
$P R E=\frac{\mid \text { Measured-Predicted } \mid}{\text { Measured }} \times 100 \%=\frac{|3,000-2,775|}{3,000} \times 100 \%=7.5 \%$
Table 6 shows PRE for each of the three models, shown in Table 5. Figure 8 shows MATLAB code for calculation of percent relative error, PRE, for each drug compound.

```
y=resp;
Y1=-15.0*MWNPOL+4697*NPolVol+4870;
Y2=-9.533*MWNPOL+1175.0*PolFrac+4283.0;
Y3=-13320.0*NPolVol-1539.0*PolFrac+5025.0;
PRE1=(abs(Y1-y)./y)*100;
PRE2=(abs(Y2-y)./y)*100;
PRE3=(abs(Y3-y)./y)*100;
```

Figure 8: MATLAB Code for calculation of percent relative error, PRE, based on the assumption that the measured solubility is the "true" value compared with that predicted by any of the three molecular models.

Table 6: The calculated percent relative error (PRE) using the three molecular models given in Table 5. The measured solubility is considered as the "true" value versus those given by such models.

| NAME | PRE1 | PRE2 | PRE3 | NAME | PRE1 | PRE2 | PRE3 |
| :--- | ---: | ---: | ---: | :--- | ---: | ---: | ---: |
| 1,6-Cleve's acid | 8 | 5 | 5 | Fenoprofen | 50 | 43 | 47 |
| 1_naphthol | 8 | 3 | 4 | Fenpiclonil | 293 | 308 | 346 |
| $2,4,5-$ <br> trichlorophenol | 8 | 13 | 11 | Fludrocortisone | 46 | 37 | 32 |
| 2,4-DB | 61 | 67 | 72 | Flufenacet | 17 | 32 | 16 |
| 2,6- <br> Dibromoquinon <br> e-4-chlorimide | 50 | 78 | 88 | Flumequine | 44 | 53 | 71 |
| 2-Amino-5- <br> bromobenzoic <br> acid | 30 | 38 | 52 | Flumioxazin | 527 | 652 | 782 |
| 2-Cyclohexyl- |  |  |  |  |  |  |  |
| 4-6- <br> dinitrophenol | 121 | 133 | 136 | Flurbiprofen | 105 | 97 | 100 |
| 2-Ethyl-1- <br> hexanol | 26 | 7 | 1 | Fluspirilene | 88 | 55 | 44 |
| 2-Naphthol | 353 | 317 | 376 | Fumaric acid | 5 | 7 | 1 |
| 3,4- |  |  |  |  |  |  |  |
| Dinitrobenzoic <br> acid | 7 | 0 | 11 | Furazolidone | 102 | 118 | 109 |
| 4-Amino-2- <br> sulfobenzoic <br> acid | 10 | 4 | 34 | Ganciclovir | 19 | 15 | 21 |
| 4-iodophenol | 34 | 31 | 5 | Glipizide | 376 | 566 | 545 |
| 5- |  |  |  |  |  |  |  |
| Aminosalicylic <br> acid | 321 | 322 | 336 | Gluconolactone | 41 | 38 | 38 |
| 5-Bromo-2,4- <br> dihydroxybenzo <br> ic acid | 8 | 19 | 27 | Glutamic acid | 6 | 6 | 7 |
| Acetaminophen | 16 | 19 | 16 | Glycine | 20 | 21 | 25 |
| Acetamiprid | 20 | 20 | 19 | Glyphosate | 11 | 7 | 11 |
| Acetanilide | 5 | 13 | 10 | Guaifenesin | 34 | 37 | 37 |
| Acetazolamide | 11 | 20 | 14 | Guanine | 403 | 430 | 414 |
| Acetochlor | 0 | 6 | 15 | Haloperidol | 10 | 17 | 5 |
| Acetylacetone | 23 | 29 | 31 | Heptabarbital | 5 | 5 | 10 |
| Acibenzolar-S- <br> methyl | 222 | 226 | 263 | Hexazinone | 44 | 43 | 42 |
| Acrylamide | 26 | 30 | 31 | Hexobarbital | 2 | 1 | 3 |
| Acylonitrile | 8 | 17 | 17 | Histidine | 23 | 23 | 24 |
| Adenine | 28 | 31 | 24 | \begin{tabular}{l}
\end{tabular} | zide |  |  |
| Adenosine | 49 | 34 | Hydrocortisone | 42 | 45 | 64 |  |
|  |  |  |  |  |  |  |  |

© 2019 Life Science Informatics Publication All rights reserved

| NAME | PRE1 | PRE2 | PRE3 | NAME | PRE1 | PRE2 | PRE3 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Adipic acid | 18 | 20 | 19 | Hydroflumethiazide | 3 | 21 | 15 |
| Aldicarb | 16 | 20 | 20 | Hydroquinone | 21 | 25 | 21 |
| Allobarbital | 3 | 7 | 16 | Hydroxyphenamate | 33 | 36 | 36 |
| Allopurinol | 579 | 603 | 573 | Hydroxy-proline | 32 | 33 | 33 |
| Alochlor | 2 | 7 | 13 | Hymexazol | 17 | 19 | 23 |
| Alpha-acetylbutyrolactone | 29 | 32 | 33 | Hyoscyamine | 43 | 44 | 44 |
| Alprenolol | 8 | 19 | 32 | Ibuprofen | 68 | 50 | 43 |
| Amantadine | 0 | 11 | 4 | Idoxuridine | 48 | 30 | 9 |
| Amitriptyline | 122 | 96 | 92 | Imazapyr | 37 | 36 | 36 |
| Amobarbital | 3 | 1 | 7 | Imazaquin | 2 | 7 | 19 |
| Ancymidol | 16 | 16 | 9 | Imazethapyr | 30 | 28 | 26 |
| Aniline | 13 | 22 | 17 | Indoprofen | 1557 | 1578 | 1723 |
| Antipyrine | 46 | 49 | 47 | Iridomyrmecin | 0 | 11 | 14 |
| ANTU( $\alpha$ Naphthylthioure a) | 0 | 4 | 10 | Isoflurophate | 20 | 24 | 31 |
| Arabinose | 36 | 36 | 35 | Isoleucine | 17 | 24 | 27 |
| Ascorbic acid | 36 | 34 | 35 | Isoniazid | 27 | 29 | 32 |
| Aspartic acid | 1 | 1 | 3 | Isophorone | 12 | 24 | 25 |
| Aspirin | 11 | 11 | 8 | Ketanserin | 16 | 39 | 42 |
| Asulam | 20 | 17 | 16 | Khellin | 17 | 15 | 14 |
| Atropine | 41 | 43 | 42 | Lindane | 209 | 245 | 239 |
| Azathioprine | 25 | 42 | 45 | Linuron | 47 | 55 | 60 |
| Azintamide | 32 | 31 | 31 | Lomefloxacin | 44 | 38 | 40 |
| Baclofen | 36 | 37 | 35 | Malathion | 13 | 7 | 7 |
| Badische acid | 0 | 3 | 13 | Maprotiline | 164 | 133 | 129 |
| Barban | 148 | 158 | 168 | Methocarbamol | 62 | 61 | 61 |
| Barbital | 13 | 16 | 23 | Methomyl (Lannate) | 26 | 29 | 31 |
| Bendiocarb | 20 | 19 | 17 | Methylparaben | 38 | 35 | 44 |
| Benzidine | 19 | 12 | 24 | Metoclopramide | 11 | 11 | 5 |
| Benzocaine | 16 | 9 | 10 | Metronidazole | 11 | 10 | 15 |
| Benzoic acid | 11 | 5 | 10 | Miconazole | 92 | 157 | 190 |
| Benzylimidazol <br> e | 12 | 4 | 13 | Minoxidil | 35 | 38 | 48 |
| Bromogramine | 67 | 73 | 113 | Nadolol | 77 | 77 | 78 |
| Bronidox | 41 | 36 | 39 | Nalidixic acid | 61 | 59 | 54 |
| Bupivacaine | 5 | 18 | 39 | Naloxone | 39 | 32 | 18 |
| Butamben | 1595 | 1459 | 1410 | Naproxen | 206 | 191 | 201 |
| Butylparaben | 1404 | 1342 | 1451 | Niflumic acid | 211 | 234 | 220 |
| Capric acid | 86 | 61 | 43 | Nitrofurantoin | 60 | 73 | 56 |
| Caproic acid | 4 | 13 | 16 | Norfloxacin | 28 | 23 | 24 |

© 2019 Life Science Informatics Publication All rights reserved

| NAME | PRE1 | PRE2 | PRE3 | NAME | PRE1 | PRE2 | PRE3 |
| :--- | ---: | ---: | ---: | :--- | ---: | ---: | ---: |
| Carbamazepine | 1576 | 1536 | 1704 | Nortriptyline | 52 | 35 | 35 |
| Carbofuran | 13 | 8 | 7 | Ofloxacin | 64 | 57 | 49 |
| Carfentrazone- <br> ethyl | 25 | 57 | 51 | Oxytetracycline | 75 | 52 | 30 |
| Carisoprodol | 4 | 1 | 13 | p-Aminobenzoic <br> acid | 33 | 35 | 32 |
| Carmustine | 8 | 3 | 9 | p-Aminosalicylic <br> acid | 110 | 110 | 114 |
| Carnosine | 39 | 38 | 38 | Papaverine | 2 | 0 | 6 |
| Carprofen | 196 | 207 | 250 | p-Fluorobenzoic <br> acid | 20 | 18 | 16 |
| Carvedilol | 36 | 19 | 10 | Phenacetin | 330 | 291 | 261 |
| Cephalothin | 54 | 37 | 19 | Phenantroline | 16 | 21 | 12 |
| Chloramphenic <br> ol | 28 | 17 | 17 | Phenazopyridine | 161 | 160 | 162 |
| Chlorphenirami <br> ne | 21 | 27 | 33 | Phenobarbital | 7 | 9 | 13 |
| Chlorpromazine | 283 | 276 | 286 | Phenolphthalein | 33 | 30 | 23 |
| Chlorthalidone | 1432 | 1725 | 2013 | Phenylbutazone | 129 | 139 | 99 |
| Chlorzoxazone | 250 | 255 | 250 | Phenytoin | 74 | 74 | 85 |
| Cimetidine | 30 | 29 | 28 | Phthalazine | 22 | 28 | 24 |
| Ciprofloxacin | 8 | 6 | 24 | Phthalic acid | 8 | 7 | 4 |
| Corticosterone | 603 | 609 | 604 | Phthalimide | 41 | 36 | 34 |
|  |  |  |  | p- <br> Hydroxybenzoic |  |  |  |
| Cortisone | 396 | 452 | 525 | Acid | 2 | 4 | 0 |
| Crotonic Acid | 16 | 21 | 23 | Picloram | 27 | 40 | 28 |
| Cumic Acid | 52 | 39 | 42 | Picric Acid | 10 | 0 | 16 |
| Cyanazine | 30 | 33 | 26 | Pindolol | 55 | 49 | 52 |
| Cyanuric Acid | 26 | 34 | 15 | Piroxicam | 162 | 202 | 238 |
| Cyclizine | 27 | 35 | 37 | Praziquantel | 345 | 338 | 341 |
| Cyclobarbital | 14 | 16 | 19 | Prednisolone | 467 | 531 | 615 |
| Cycloleucine | 21 | 25 | 24 | Primidone | 470 | 448 | 450 |
| Cyproconazole | 3 | 1 | 6 | Procaine | 27 | 32 | 36 |
| Cyprodinil | 138 | 125 | 136 | Propranolol | 23 | 13 | 6 |
| Cystine | 36 | 45 | 54 | Propylparaben | 548 | 503 | 489 |
| Cytosine | 47 | 47 | 49 | Quinidine | 1080 | 1071 | 1072 |
| Danofloxacin | 45 | 33 | 18 | Quinine | 39 | 40 | 40 |
| Dapsone | 1549 | 1582 | 1769 | Ranitidine | 31 | 29 | 36 |
| Dehydroacetic <br> Acid | 21 | 19 | 18 | Salicylamide | 77 | 71 | 74 |
| Deoxycorticoste <br> rone | 901 | 944 | Salicylic acid | 63 | 59 | 63 |  |
| Deprenyl | 5 | 7 | Sparfloxacin | 42 | 28 | 23 |  |
| Desipramine | 27 | 9 | 11 | Strychnine | 690 | 768 | 976 |
| Dexamethasone | 47 | 36 | 30 | Sulfacetamide | 64 | 63 | 62 |
|  |  |  |  |  |  |  |  |

© 2019 Life Science Informatics Publication All rights reserved

| NAME | PRE1 | PRE2 | PRE3 | NAME | PRE1 | PRE2 | PRE3 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Diazepam | 24 | 26 | 36 | Sulfamerazine | 1155 | 1214 | 1259 |
| Diazoxide | 44 | 52 | 61 | Sulfamethazine | 15 | 9 | 0 |
| Dicamba | 5 | 10 | 9 | Sulfamethoxazol <br> e | 334 | 360 | 385 |
| Dichlobenil | 158 | 155 | 151 | Sulfanilamide | 55 | 55 | 55 |
| Difenoconazole | 0 | 29 | 42 | Sulfathiazole | 7 | 0 | 12 |
| Difloxacin | 38 | 22 | 14 | Sulindac | 22 | 43 | 80 |
| Digallic Acid | 18 | 2 | 8 | Sulpiride | 21 | 18 | 27 |
| Diltiazem | 67 | 58 | 53 | Testosterone | 39 | 24 | 17 |
| Dimethenamid | 27 | 29 | 30 | Tetracaine | 2 | 9 | 28 |
| Dimethirimol | 4 | 11 | 14 | Tetracycline | 76 | 54 | 27 |
| Diphenydramin <br> e | 2 | 16 | 29 | Theobromine | 939 | 973 | 964 |
| Diphenylhydant oin (Phenytoin) | 59 | 59 | 69 | Theophylline | 53 | 52 | 53 |
| DL-Camphor | 112 | 85 | 88 | Thiamphenicol | 50 | 40 | 35 |
| Enrofloxacin (Baytril) | 38 | 28 | 18 | Thionazin | 13 | 12 | 12 |
| EPTC | 21 | 6 | 4 | Thymine | 3 | 1 | 6 |
| Equilin | 1295 | 1215 | 1328 | Thymol | 15 | 0 | 0 |
| Ethinamate | 1 | 8 | 10 | Tolmetin | 85 | 80 | 79 |
| Ethirimol | 28 | 19 | 14 | Trichloromethiaz ide | 4 | 29 | 29 |
| Ethofumesate | 28 | 32 | 37 | Trimethoprim | 9 | 5 | 6 |
| Ethohexadiol | 23 | 32 | 37 | Trimipramine | 192 | 146 | 80 |
| Ethoprop | 14 | 21 | 23 | Tryptamine | 72 | 59 | 72 |
| Ethylparaben | 280 | 260 | 261 | Uracil | 14 | 14 | 3 |
| Famotidine (Pepcid) | 32 | 17 | 2 | Verapamil | 69 | 68 | 103 |
| Fenbufen | 603 | 565 | 557 | Warfarin | 158 | 168 | 194 |

From Table 6, it can be seen that the model overestimates the solubility of the following eleven drug compounds: butamben, butylparaben, carbamazepine, chlorthalidone, dapsone, deoxycorticosterone, equilin, indoprofen, quinidine, sulfamerazine, and theobromine. Scrutinizing the experimental solubility data, one can see that they all fall below $200 \mathrm{mg} / \mathrm{L}$, except for theobromine, which amounts to $330 \mathrm{mg} / \mathrm{l}$; however, the solubility of theobromine is also reported as $610 \mathrm{mg} / \mathrm{L}$ [8]. Another source [10] reported the value as: "One gram dissolves in about 200 mL water, 150 mL boiling water". The latter value amounts to $5,000 \mathrm{mg} / \mathrm{L}$. The three models predict a solubility value of $3,429,3540$, and $3512 \mathrm{mg} / \mathrm{L}$, respectively. What I argue here regarding theobromine aqueous solubility will extend to solubility of any other drug molecule, as well. The variation in experimental solubility is quite significant and that it will be very difficult to rely on one reported value of aqueous solubility of a given drug molecule. This opens the door for a future work to consider a more giant set of drug aqueous solubility data and make further classification, based on the reported value as practically insoluble, barely or slightly soluble, relatively soluble, soluble, and highly soluble subsets of drug molecules. The last important point to pinpoint here is simply what drives solvation process of a drug in water. Based on the arrived conclusion that at the top of the examined five predictors, it was found that $M W_{N P O L}\left[\frac{g}{m o l}\right]=(1-$ PoleFrac $) \times M W$ ranks number one among the rest of the list. Let us expatiate a little bit on this predictor. Notice that the value of $M W_{N P O L}$ will grow up by two independent variables: The non-polar fraction given by ( 1 - PoleFrac) and the size of the molecule itself given by the molecular mass, MW. The multiplication of such two molecular properties should tell us about the influence of the hydrophobic non-polar core of the molecule on the overall solvation process. If we scrutinize this first predictor throughout the examined three models, we will find that the slope is negative for $M W_{N P O L}$ ( $a$ term in both equations 29 and 30). Although it will be too early to explain in a more detail the contribution of each molecular predictor, but one can say at this stage that the since the slope is negative it simply implies that the anti-solvation (i.e., phase separation) process is entropically driven, mainly by water molecules surrounding and surmounting the organic solute. The solvation process will accommodate the non-polar organic moiety into a polar medium, like water. This being the case, water molecules surrounding an organic molecule are characterized by a higher degree of order at this polar/non-polar interface, where they assume a locally ordered, quasi-solid structure (a "cagelike" structure, clathrate, or iceberg structure) with some loss of H-bonding capacity. As phase separation between a substantially hydrophobic (high $M W_{N P O L}$ ) drug and water is thermodynamically more stable than the monodisperse case (i.e., solution), it turns out that $\Delta \mathbf{S}_{\text {solvent }}$ is the predominant driving force that underlies the process of phase separation in this case. The effect of $\Delta \mathrm{S}_{\text {solvent }}$ is usually referred to as a hydrophobic or entropic effect [11].
© 2019 Life Science Informatics Publication All rights reserved

## 4. CONCLUSION

The supervised machine learning techniques can be used to decipher the relationship between the response on one side and predictor variables on another side. The unsupervised machine learning techniques, on the other hand, can be used to weigh the importance of predictor variables relative to each other without the influence of the response variable. In general, Using MATLAB supervised and unsupervised machine learning algorithms, the drug aqueous solubility data can be best described by the first three important molecular properties: $M_{\text {NPOL }}$, NPolVol, and PolFrac, as the third refining or tuning-up factor (weight parameter in curve-fitting). MW ${ }_{\text {NPOL }}$ is thought to represent the entropically driven hydrophobic interactions which favor phase separation (antisolvation) over making up a solution. The robust, linear regression method was used to quantitatively predict the relationship between aqueous solubility and the above three selected predictors. The robust approach relies on the least absolute residuals (LAR) optimization criterion, which tries to find a curve that minimizes the absolute difference of the residuals, rather than the squared differences. Therefore, extreme values have a lesser influence on the fit. The adjusted $\mathrm{R}^{2}$ was found to be around 0.97 for any of the three models given by equations 29 through 31 and as shown in detail in Table 5. The percent relative error (PRE) was also calculated for each individual drug molecule using the above three models while assuming that the true value of solubility is the experimentally measured and reported value. It was found that the three models overestimate the aqueous solubility of less soluble materials, i.e., below $200 \mathrm{mg} / \mathrm{L}$.

## ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

## HUMAN AND ANIMAL RIGHTS

No Animals/Humans were used for studies that are base of this research.

## CONSENT FOR PUBLICATION

Not applicable.

## AVAILABILITY OF DATA AND MATERIALS

The authors confirm that the data supporting the findings of this research are available within the article.

## FUNDING

None

## CONFLICT OF INTEREST

There is no conflict of interest.

## REFERENCES

1. Al-Malah, Kamal I. Optimization of Drug Solubility Using Aspen Plus: Acetaminophen Solubility, a Case Study. Int J Pharmacognosy 2018; 5(11): 724-31. http://ijpjournal.com/bft-article/optimization-of-drug-solubility-using-aspen-plus-acetaminophen-solubility-a-casestudy/?view=fulltext.
2. Erić, S., Kalinić, M., Popović, A., Zloh, M., Kuzmanovski, I. Prediction of aqueous solubility of drug-like molecules using a novel algorithm for automatic adjustment of relative importance of descriptors implemented in counter-propagation artificial neural networks. International Journal of Pharmaceutics 2012; 437(1-2): 232-241. ISSN 0378-5173. (http://www.sciencedirect.com/science/article/pii/S0378517312008174).
3. Sun, H., Pranav, Sh., Nguyen, K., Yu, KR, Kerns, E., Kabir, Md, Wang Y., Xu X. Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity. Bioorganic \& Medicinal Chemistry 2019; 27(14): 3110-3114. ISSN 0968-0896, (http://www.sciencedirect.com/science/article/pii/S0968089619303475).
4. Al-Malah, K. Aqueous solubility of a diatomic molecule as a function of its size \& electronegativity difference. J Mol Model 2011; 17:325-331.
5. Al-Malah, K. Aqueous solubility of a simple (single-carbon) organic molecule as a function of its size \& dipole moment. J Mol Model 2011; 17:1029-1034.
6. Al-Malah, K. Prediction of aqueous solubility of organic solvents as a function of selected molecular properties. Journal of Pharmaceutics \& Drug Delivery Research 2012; 1(2): 1-7 https://www.scitechnol.com/prediction-of-aqueous-solubility-of-organic-solvents-as-a-function-of-selected-molecular-properties-10x8.pdf.
7. Cao, D-S, Xu, Q, Liang, Y-Z, Chen, X, Li, H-D. Prediction of aqueous solubility of druglike organic compounds using partial least squares, back-propagation network and support vector machine. J. Chemometrics, 2010; 24(9): 584-595. (www.interscience.wiley.com)
8. Yalkowsky, S, He, Y., Jain, P. Handbook of Aqueous Solubility Data. CRC Press, Taylor \& Francis Group, Boca Raton, Florida, USA. ISBN-13: 978-1-4398-0246-5 (E-book-PDF), 2010.
9. Rahm, M, Zeng, T, Hoffmann, R. Electronegativity Seen as the Ground-State Average Valence Electron Binding Energy". Journal of the American Chemical Society 2019; 141: 342-351.
10. O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry. 2013; p. 1719.
11. Al-Malah, K. A Macroscopic Model for Apparent Protein Adsorption Equilibrium at Hydrophobic Solid/Liquid Interfaces, Ph.D. Dissertation, Oregon State University, Corvallis.1993; p. 9-10.
